INDEX Volume Twenty-Five—January through December 1991 DICP, The Annals of Pharmacotherapy JANUARY Pages 1-114 MAY Pages 451-572 OCTOBER Pages 1039-1158 FEBRUARY Pages 115-226 JUNE Pages 573-702 NOVEMBER Pages 1159-1294 MARCH Pages 227-338 JULY/AUGUST Pages 703-906 DECEMBER Pages 1295-1444 APRIL Pages 339-450 SEPTEMBER Pages 907-1038 SUBJECT INDEX American Council on Pharmaceutical Education, see Associ- Aspirin, administration delay, myocardial infarction (A) 1096; ation News (NC) compared with dipyridamole, angioplasty (DIAS) 747; glu- American Pharmaceutical Association, see Association News cose-6-phosphate dehydrog: deficiency (SR) 1074; topi- (NC) cal, postherpetic neuralgia (DIAS) 1077 a Amikacin, postantibiotic effect (A) 156 Association News (NC), AACP 1990-91 GAPS Awards, 572; Amiloride, compared with felodipine (FF) 1198; lung disease, AACP Faculty Salary Survey, 701; ACCP Election Results, cystic fibrosis (DIAS) 1340 226; ACCP Issues Guidelines for Clinical Pharmacokinetics Amino acids, biochemical markers, nutrition support (A) 265 Service, 1037; ACCP Pharmacotherapy Self-Assessment Pro- Abate, Marie A., USPC drug information development pro- Aminoglycosides, conversion to ceftriaxone, cost (L) 319; gram, 1037; ACCP Position on Entry-Level Degree for Phar- grams (NC) 450 dosage schedules (L) 558; pharmacokinetics, two- vs. three- macy, 572; ACPE Intent to Revise Standards—Status Report, Absorption, acetylcysteine, activated charcoal (TC) 1081; point method (TM) 635, (L) 1141; postantibiotic effect (A) 905; APhA comments on Medicare Home Drug Infusion, digoxin, quinidine, interaction, sucralfate (SR) 745; lidocaine, 154; with beta-lactams, synergy (A) 972 1432; APhA Joined by NCL for a Third Class of Drugs, 905; age (SR) 463 Aminophylline, admixture, parenteral nutrition (CC) 279 APhA-ASP Task Force on Revision of Accreditation and Academy of Students of Pharmacy, see Association News Aminosalicylic acid, availability (NC) 1430 Standards Guidelines, 1157; BPS Certification Examination (NC) Amitriptyline, compared with sertraline (FF) 954; pharmacoki- for Nutrition Support on Schedule, 905; BPS Completes Phar- Acebutolol, beta-adrenergic receptor response, racial groups (A) netics (TM) 1368 macotherapy Validation Exercise, 905; BPS Pharmacotherapy 827; pharmacokinetics (DSP) 965; pharmacology (DSP) 962 Amph icin B, compatibility, magnesium sulfate (RPR) 123; Examination Developed; Psychopharmacy Petition Received, Acetazolamide, confused with acetohexamide (L) 100 hepatotoxicity (L) 559 226; BPS Sets Nutrition Certification Requirements, 1038; Acetoacetate, biochemical marker, nutrition support (A) 265 Ampicillin, postantibiotic effect (A) 155 Council on Student Affairs Founded, 1293; FIP Congress Acetohexamide, confused with acetazolamide (L) 100 Amrinone, congestive heart failure, review (A) 1352 Pharmacy Information Section Program, 701; JCPP Needs Acetylcholine, intraocular, hypotension, bradycardia (CR) 1178 Analgesia, meperidine, conc i P P i (RPR) Comments on Mission, 1037; NASCDS Commissioned Sur- Acetylcysteine, absorption, activated charcoal (TC) 1081 724; vapreotide (L) 1136 vey of Pharmacy School Faculty, 450; 19th European Sympo- Actisomide, pharmacokinetics, tolerance (RPR) 231 Anaphylaxis, tetanus toxoid (L) 870; vitamin K, (L) 871 sium on Clinical Pharmacy, 226; Research Institute Awards Acyclovir, compared with foscarnet sodium (FF) 43; no interac- Anesthesia, neuromuscular blocking agents, pharmacology (A) $125 000 in Grants, 1430; Society of Infectious Diseases tion, cyclosporine (L) 316; utilization (PEP) 1374 54 Pharmacists Founded, 450; Society of Infectious Diseases Addicti. see Ty P di. e Angina pectoris, felodipine, review (FF) 1199 Pharmacists Incorporates, 1293 Adenosine, compared with verapamil, supraventricular tachy- Angioplasty, dipyridamole (DIAS) 747 Asthma, corticosteroids, review (PA) 72; pathogenesis (PA) cardia (DIAS) 749; stress testing (FF) 1089 Angiotensin-converting enzyme inhibitors, congestive heart 993; patient education 638 (PA), (E) 668 Adrenocorticotropic hormone, myasthenia gravis (A) 1105 failure, review (A) 1349 Atenolol, alcohol withdrawal (DIAS) 31; beta-adrenergic recep- Age, lidocaine absorption (SR) 463; lymphocyte betap-adrener- An Opinion, see also, Editorials; Coulston, Daniel R., Hepati- tor response, racial groups (A) 825; pharmacokinetics (DSP) gic receptor responsiveness (A) 532 tis B Vaccine, 671; Galinsky, Raymond E., Nickman, Nan- 965; pharmacology (DSP) 962 Agranulocytosis, enalapril (CR) 461; erythromycin (L) 1136 cy A., Pharmacists and the Mandate of Pharmaceutical Care, Atracurium, pharmacodynamics (A) 59; pharmacokinetics (A) AIDS, clofazimine, Mycobacterium avium (FF) 528; cost, outpa- 431; Green, Jeffrey A., The Healthcare Professional of the 59 tient (PEC) 414; counseling, testing services (NC) 1430; cy- Future: Function Based upon Competence, 205; Hatoum, Atropine, pediatric cardiopulmonary resuscitation (TC) 766 tomegalovirus, foscarnet sodium, review (FF) 41; dextran Hind T., Viasses, Peter H., Patient Outcome and the Future Attention deficit disorder with hyperactivity, bupropion (DIAS) 606; FDA position (RC) 428; home care (A) 847; in- Practice of Pharmacy, 208; Vitillo, Josephine A., Lesar, (DSP) 1209; clomipramine (DSP) 1209; clorgiline (DSP) cidence, Europe (NC) 114, women (NC) 114; mortality (NC) Timothy S., Preventing Medication Prescribing Errors, 1388; 1209; dextroamphetamine (DSP) 1207; imipramine (DSP) P33n8e;u mpoecnytsatmiisd incear,i ninie php rotoxicityi , thryeipmeeratkhoap lreimmi/a ae (RIfP R) 1Hi1 71; GVerneee,s , To11m3 2 B., Pharmacist—Physician Interaction: A Battle of t1r2a07n;y lcmyeptrhoymlipnhee ni(dDaStPe) (1D2S0P9) 1208; review (DSP) 1207; zole (DIAS) 941 Antacids, interaction, ciprofloxacin, review (DIAS) 473, Azathioprine, myasthenia gravis (A) 1105 Albumin, admixture, parenteral nutrition (CC) 278; utili quinol (DIR) 1250 Azlocillin, postantibiotic effect (A) 155 physician intervention (RPR) 239 Antibiotics, dosing frequencies, cost (PEC) 546; parenteral, Aztreonam, myelosuppression (CR) 594; postantibiotic effect Albuterol, see also, Volmax compared with oral ciprofloxacin (PEP) 857; postantibiotic ef- (A) 154 Allergy, clindamycin (L) 317; phenytoin (CR) 929 fect (A) 153; prophylaxis, coronary bypass surgery (TC) 478; Alprostadil, congenital heart disease, neonatal transport (PED) restricted, utilization (IR) 662 408; impotence (DIAS) 363 Antibodies, monoclonal, ES, adverse reactions (FF) 788, phar- Alteplase, administration delay, myocardial infarction (A) 1098; macokinetics (FF) 787, review (FF) 784; human, adverse re- compared with streptokinase (L) 1271; neonatal thrombosis actions (FF) 781, pharmacokinetics (FF) 780, pharmacology (PED) 853 (FF) 778, review (FF) 778 Altretamine, adverse reactions (FF) 150; pharmacokinetics (FF) Anticonvulsants, pharmacokinetics (A) 979; vitamin E (DIAS) 147; pharmacology (FF) 147; review (FF) 146 362 Bacillus Calmette-Guerin vaccine, adverse reactions, review Aluminum hydroxide, kidney failure (DIAS) 943 Antidepressants, cocaine abuse (A) 818; tricyclic, pharmacoki- (A) 1361; superficial bladder cancer, review (A) 1355 Amantadine, cocaine abuse (A) 820; neurotoxicity, renal trans- netics (TM) 1368 Bacteria, susceptibility, cefi ime, cip in, to- plant (CR) 1175 Antiinflammatory drugs, asthma, review (PA) 998; nonster- bramycin, pharmacokinetics (RPR) 1050 Amb chloride, myasthenia gravis (A) 1103 oidal, CNS toxicity (CR) 1066, generic—brand name knowl- Baker, Danial E., USPC drug information development pro- Ambulatory care, cost, compared with disease progression, edge (L) 1138, package inserts, Saudi Arabia compared with grams (NC) 450 HIV population (PEC) 414; crug information, penicillin US (IR) 863 BCG, see Bacillus Calmette-Guerin vaccine (RPR) 925; prescribing patterns, geriatrics (G) 186, Saudi Antipsychotics, cocaine abuse (A) 821 Beck, Diane E., AACP Lyman Award (NC) 572 Arabia (IR) 90; psychotherapeutic prescriptions (PEP) 85 Aortic dissection, acute, esmolol (CR) 735 Belgium, package inserts (IR) 1002 American Association of Colleges of Pharmacy, see Associa- Apnea, phenothiazine (CR) 244 Benet, Leslie Z., AACP Volwiler Research Achievement (NC) tion News (NC) Arrhythmia, famotidine (L) 315 572 American College of Clinical Pharmacy, see Association Arthritis, rheumatoid, hydroxychloroquine pharmacokinetics Benzodiazepines, alcohol withdrawal (DIAS) 31; utilization News (NC) (RPR) 1302 (PEP) 1374 1432 = DICP,The Annals of Pharmacotherapy *® 1991 December, Volume 25 INDEX Volume Twenty-Five—January through December 1991 DICP, The Annals of Pharmacotherapy JANUARY Pages 1-114 MAY Pages 451-572 OCTOBER Pages 1039-1158 FEBRUARY Pages 115-226 JUNE Pages 573-702 NOVEMBER Pages 1159-1294 MARCH Pages 227-338 JULY/AUGUST Pages 703-906 DECEMBER Pages 1295-1444 APRIL Pages 339-450 SEPTEMBER Pages 907-1038 SUBJECT INDEX American Council on Pharmaceutical Education, see Associ- Aspirin, administration delay, myocardial infarction (A) 1096; ation News (NC) compared with dipyridamole, angioplasty (DIAS) 747; glu- American Pharmaceutical Association, see Association News cose-6-phosphate dehydrog: deficiency (SR) 1074; topi- (NC) cal, postherpetic neuralgia (DIAS) 1077 a Amikacin, postantibiotic effect (A) 156 Association News (NC), AACP 1990-91 GAPS Awards, 572; Amiloride, compared with felodipine (FF) 1198; lung disease, AACP Faculty Salary Survey, 701; ACCP Election Results, cystic fibrosis (DIAS) 1340 226; ACCP Issues Guidelines for Clinical Pharmacokinetics Amino acids, biochemical markers, nutrition support (A) 265 Service, 1037; ACCP Pharmacotherapy Self-Assessment Pro- Abate, Marie A., USPC drug information development pro- Aminoglycosides, conversion to ceftriaxone, cost (L) 319; gram, 1037; ACCP Position on Entry-Level Degree for Phar- grams (NC) 450 dosage schedules (L) 558; pharmacokinetics, two- vs. three- macy, 572; ACPE Intent to Revise Standards—Status Report, Absorption, acetylcysteine, activated charcoal (TC) 1081; point method (TM) 635, (L) 1141; postantibiotic effect (A) 905; APhA comments on Medicare Home Drug Infusion, digoxin, quinidine, interaction, sucralfate (SR) 745; lidocaine, 154; with beta-lactams, synergy (A) 972 1432; APhA Joined by NCL for a Third Class of Drugs, 905; age (SR) 463 Aminophylline, admixture, parenteral nutrition (CC) 279 APhA-ASP Task Force on Revision of Accreditation and Academy of Students of Pharmacy, see Association News Aminosalicylic acid, availability (NC) 1430 Standards Guidelines, 1157; BPS Certification Examination (NC) Amitriptyline, compared with sertraline (FF) 954; pharmacoki- for Nutrition Support on Schedule, 905; BPS Completes Phar- Acebutolol, beta-adrenergic receptor response, racial groups (A) netics (TM) 1368 macotherapy Validation Exercise, 905; BPS Pharmacotherapy 827; pharmacokinetics (DSP) 965; pharmacology (DSP) 962 Amph icin B, compatibility, magnesium sulfate (RPR) 123; Examination Developed; Psychopharmacy Petition Received, Acetazolamide, confused with acetohexamide (L) 100 hepatotoxicity (L) 559 226; BPS Sets Nutrition Certification Requirements, 1038; Acetoacetate, biochemical marker, nutrition support (A) 265 Ampicillin, postantibiotic effect (A) 155 Council on Student Affairs Founded, 1293; FIP Congress Acetohexamide, confused with acetazolamide (L) 100 Amrinone, congestive heart failure, review (A) 1352 Pharmacy Information Section Program, 701; JCPP Needs Acetylcholine, intraocular, hypotension, bradycardia (CR) 1178 Analgesia, meperidine, conc i P P i (RPR) Comments on Mission, 1037; NASCDS Commissioned Sur- Acetylcysteine, absorption, activated charcoal (TC) 1081 724; vapreotide (L) 1136 vey of Pharmacy School Faculty, 450; 19th European Sympo- Actisomide, pharmacokinetics, tolerance (RPR) 231 Anaphylaxis, tetanus toxoid (L) 870; vitamin K, (L) 871 sium on Clinical Pharmacy, 226; Research Institute Awards Acyclovir, compared with foscarnet sodium (FF) 43; no interac- Anesthesia, neuromuscular blocking agents, pharmacology (A) $125 000 in Grants, 1430; Society of Infectious Diseases tion, cyclosporine (L) 316; utilization (PEP) 1374 54 Pharmacists Founded, 450; Society of Infectious Diseases Addicti. see Ty P di. e Angina pectoris, felodipine, review (FF) 1199 Pharmacists Incorporates, 1293 Adenosine, compared with verapamil, supraventricular tachy- Angioplasty, dipyridamole (DIAS) 747 Asthma, corticosteroids, review (PA) 72; pathogenesis (PA) cardia (DIAS) 749; stress testing (FF) 1089 Angiotensin-converting enzyme inhibitors, congestive heart 993; patient education 638 (PA), (E) 668 Adrenocorticotropic hormone, myasthenia gravis (A) 1105 failure, review (A) 1349 Atenolol, alcohol withdrawal (DIAS) 31; beta-adrenergic recep- Age, lidocaine absorption (SR) 463; lymphocyte betap-adrener- An Opinion, see also, Editorials; Coulston, Daniel R., Hepati- tor response, racial groups (A) 825; pharmacokinetics (DSP) gic receptor responsiveness (A) 532 tis B Vaccine, 671; Galinsky, Raymond E., Nickman, Nan- 965; pharmacology (DSP) 962 Agranulocytosis, enalapril (CR) 461; erythromycin (L) 1136 cy A., Pharmacists and the Mandate of Pharmaceutical Care, Atracurium, pharmacodynamics (A) 59; pharmacokinetics (A) AIDS, clofazimine, Mycobacterium avium (FF) 528; cost, outpa- 431; Green, Jeffrey A., The Healthcare Professional of the 59 tient (PEC) 414; counseling, testing services (NC) 1430; cy- Future: Function Based upon Competence, 205; Hatoum, Atropine, pediatric cardiopulmonary resuscitation (TC) 766 tomegalovirus, foscarnet sodium, review (FF) 41; dextran Hind T., Viasses, Peter H., Patient Outcome and the Future Attention deficit disorder with hyperactivity, bupropion (DIAS) 606; FDA position (RC) 428; home care (A) 847; in- Practice of Pharmacy, 208; Vitillo, Josephine A., Lesar, (DSP) 1209; clomipramine (DSP) 1209; clorgiline (DSP) cidence, Europe (NC) 114, women (NC) 114; mortality (NC) Timothy S., Preventing Medication Prescribing Errors, 1388; 1209; dextroamphetamine (DSP) 1207; imipramine (DSP) P33n8e;u mpoecnytsatmiisd incear,i ninie php rotoxicityi , thryeipmeeratkhoap lreimmi/a ae (RIfP R) 1Hi1 71; GVerneee,s , To11m3 2 B., Pharmacist—Physician Interaction: A Battle of t1r2a07n;y lcmyeptrhoymlipnhee ni(dDaStPe) (1D2S0P9) 1208; review (DSP) 1207; zole (DIAS) 941 Antacids, interaction, ciprofloxacin, review (DIAS) 473, Azathioprine, myasthenia gravis (A) 1105 Albumin, admixture, parenteral nutrition (CC) 278; utili quinol (DIR) 1250 Azlocillin, postantibiotic effect (A) 155 physician intervention (RPR) 239 Antibiotics, dosing frequencies, cost (PEC) 546; parenteral, Aztreonam, myelosuppression (CR) 594; postantibiotic effect Albuterol, see also, Volmax compared with oral ciprofloxacin (PEP) 857; postantibiotic ef- (A) 154 Allergy, clindamycin (L) 317; phenytoin (CR) 929 fect (A) 153; prophylaxis, coronary bypass surgery (TC) 478; Alprostadil, congenital heart disease, neonatal transport (PED) restricted, utilization (IR) 662 408; impotence (DIAS) 363 Antibodies, monoclonal, ES, adverse reactions (FF) 788, phar- Alteplase, administration delay, myocardial infarction (A) 1098; macokinetics (FF) 787, review (FF) 784; human, adverse re- compared with streptokinase (L) 1271; neonatal thrombosis actions (FF) 781, pharmacokinetics (FF) 780, pharmacology (PED) 853 (FF) 778, review (FF) 778 Altretamine, adverse reactions (FF) 150; pharmacokinetics (FF) Anticonvulsants, pharmacokinetics (A) 979; vitamin E (DIAS) 147; pharmacology (FF) 147; review (FF) 146 362 Bacillus Calmette-Guerin vaccine, adverse reactions, review Aluminum hydroxide, kidney failure (DIAS) 943 Antidepressants, cocaine abuse (A) 818; tricyclic, pharmacoki- (A) 1361; superficial bladder cancer, review (A) 1355 Amantadine, cocaine abuse (A) 820; neurotoxicity, renal trans- netics (TM) 1368 Bacteria, susceptibility, cefi ime, cip in, to- plant (CR) 1175 Antiinflammatory drugs, asthma, review (PA) 998; nonster- bramycin, pharmacokinetics (RPR) 1050 Amb chloride, myasthenia gravis (A) 1103 oidal, CNS toxicity (CR) 1066, generic—brand name knowl- Baker, Danial E., USPC drug information development pro- Ambulatory care, cost, compared with disease progression, edge (L) 1138, package inserts, Saudi Arabia compared with grams (NC) 450 HIV population (PEC) 414; crug information, penicillin US (IR) 863 BCG, see Bacillus Calmette-Guerin vaccine (RPR) 925; prescribing patterns, geriatrics (G) 186, Saudi Antipsychotics, cocaine abuse (A) 821 Beck, Diane E., AACP Lyman Award (NC) 572 Arabia (IR) 90; psychotherapeutic prescriptions (PEP) 85 Aortic dissection, acute, esmolol (CR) 735 Belgium, package inserts (IR) 1002 American Association of Colleges of Pharmacy, see Associa- Apnea, phenothiazine (CR) 244 Benet, Leslie Z., AACP Volwiler Research Achievement (NC) tion News (NC) Arrhythmia, famotidine (L) 315 572 American College of Clinical Pharmacy, see Association Arthritis, rheumatoid, hydroxychloroquine pharmacokinetics Benzodiazepines, alcohol withdrawal (DIAS) 31; utilization News (NC) (RPR) 1302 (PEP) 1374 1432 = DICP,The Annals of Pharmacotherapy *® 1991 December, Volume 25 Beta-blockers, see Sympatholytic agents Calcium, carbonate, kidney failure (DIAS) 945; citrate, kidney Clotrimazole, compared with fluconazole, vulvovaginal can- Beta-hydroxybutyrate, biochemical marker, nutritional support failure (DIAS) 943 didiasis (RPR) 582; utilization (PEP) 1374 (A) 267 Campbell, R. Keith, Washington State University Outstanding Cloxacillin, postantibiotic effect (A) 155 Beta-lactam agents, synergy (A) 972 Alumni Award (NC) 1038 Cocaine, abuse, amantadine (A) 820, bromocriptine (A) 820, Betamethasone, compared with hydrocortisone, dexametha- Cancer, biologic response modifiers, review (DSP) 490; blad- carbamazepine (A) 820, desipramine (A) 818, flupenthixol de- sone, asthma (PA) 73 der, BCG vaccine, review (A) 1355; ovarian, altretamine, re- canoate (A) 821, imipramine (A) 819, lithium (A) 821, mapro- Betaxolol, pharmacokinetics (DSP) 965 view (FF) 146; pain management (A) 1225; prostate, goserelin tiline (A) 819, methylphenidate hydrochloride (A) 820, Bezafibrate, rhabdomyolysis (L) 869 acetate, review (FF) 796 ine oxidase inhibitors (A) 820, done (A) 819, Binding, protein, vancomycin, Staphylococcus aureus (RPR) Candidiasis, vulvovaginal, fluconazole compared with clotrima- treatment, review (A) 818, tyrosine (A) 820 713 zole (RPR) 582 Codeine, clearance, kidney failure (A) 1219; recovering alco- Bioavailability, see Drugs, availability Capsaicin, adverse reactions (FF) 385; pharmacokinetics (FF) holic, addict (A) 49; utilization (PEP) 1374 Biochemical markers, nutrition support (A) 265 383; pharmacology (FF) 382; review (FF) 381 Colchicine, halothane hepatitis (L) 211 Biologic response modifiers, cancer (DSP) 490 Captopril, clearance, kidney failure (A) 1216; compared with Colistin, toxicity, cystic fibrosis (RPR) 1168 BIOSIS, compared with EMBASE, TOXLINE, MEDLINE, quinapril (FF) 500 Colitis, ulcerative, mesalamine (L) 1015, review (FF) 140 IDIS, Core MEDLINE, PASCAL, PHARMLINE, IPA, ad- Carbamazepine, cocaine abuse (A) 820; monitoring, children Colony-stimulating factors, cancer (DSP) 490; pharmacokinet- verse drug reactions (RPR) 1062 (PED) 1109; with phenobarbital, acute water intoxication ics (DSP) 491; toxicity (DSP) 492 Biotransformation, phenytoin, teratogenicity (PED) 987 (CR) 354 Compatibility, see Incompatibility Bisoprolol, clearance, kidney failure (A) 1219 Carbapenem agents, with beta-lactams, synergy (A) 975 Compliance, digoxin, concentration (L) 103; phenytoin, con- Bleeding, gastrointestinal, pentoxifylline (L) 315 Carbenicillin, postantibiotic effect (A) 155 centration (L) 103; subtherapeutic conc ions (L) 1016 Bleomycin, cell lethality, containers (RPR) 14; compared with Carmichael, Jannet M., president-elect, American Society of Computers, monitoring, ciprofloxacin—theophylline interaction talc, malignant pleural effusion (DIAS) 1188 Hospital Pharmacists (NC) 1431 (L) 1011 Blepharitis, chronic, I-Scrub (SR) 359 Carteolol, pharmacokinetics (DSP) 965; pharmacology (DSP) Concentrations, actisomide (RPR) 231; aminoglycosides (TM) Blood levels, see Concentrations 963 635; amitriptyline (TM) 1368; carbamazepine, children (PED) Blood pressure, phenylpropanolamine-i hacin (RPR) Case Reports, see Pharmacotherapy Case Reports 1109; desipramine (TM) 1368; digoxin, assay anomalies (SR) 234 Cations, interaction, quinolones (DIR) 1249 739, compliance (L) 103, Lanoxin vs. Lanoxicaps (RPR) Board of Pharmaceutical Specialties, see Association News ef ibiotic effect (A) 156; prophylaxis, coro- 1043, with digoxin immune Fab (RPR) 1047; digoxin immune (NC) nary bypass surgery (TC) 481 Fab, kidney failure (CR) 1315; doxepin (TM) 1368; gentami- Book Reviews, Atherosclerosis Reviews: Prevention and Nonin- Cefazolin, postantibiotic effect (A) 156; prophylaxis, coronary cin, postpartum endomyometritis (RPR) 1306; hydroxychloro- vasive Therapy of Atherosclerosis (A. Leaf, P.C. Weber), 683; bypass surgery (TC) 481 quine, rheumatoid arthritis (RPR) 1302; 3-hydroxyquinidine Bioadhesion: Possibilities and Future Trends (R. Gurny, H.E. Cefmenoxime, pharmacokinetics, bacterial susceptibility (RPR) (L) 867;imipramine (TM) 1368; meperidine, postoperative Junginger), 323; Biopharmaceutics and Clinical Pharmacoki- 1050 (RPR) 724; nortriptyline (TM) 1368; phenytoin, compliance netics (M. Gibaldi), 104; Cardiovascular Pharmacology, 3rd Cefoperazonc, postantibiotic effect (A) 156 (L) 103; procainamide, neonates (PED) 68; subtherapeutic, Edition, 440; Chemotherapy of Gynecologic Cancer, 2nd Edi- Cefotaxime, postantibiotic effect (A) 156 compliance (L) 1016; theophylline, compliance (L) 103; tion (G. Deppe), 1144; Clinical Drug Therapy: Rationales for Cefotetan, compared with cefoxitin, surgical prophylaxis (RPR) trimethopri Jen lf: h azole, Pneumocystis carinii pneu- Nursing Practice, 3rd. Edition (A.C. Abrams), 1018; CYBER- 10 monia (DIAS) 941 LOG: A Library of Applied Medical Software: Arrhythmias Cefoxitin, compared with cefotetan, surgical prophylaxis (RPR) Congestive heart failure, digoxin (L) 320; felodipine, review (A.K. Almquist), 683; Drug Regimen Review: A Process ) (FF) 1200 Guide for Pharmacists (W.G. Erwin), 105; Drug Safety in Cefpiramide, clearance, kidney failure (A) 1219 Containers, plastic, glass, bleomycin cell lethality (RPR) 14 Pregnancy (P.1. Folb, M.N.G. Dukes), 1017; Drug Therapy in Ceftazidime, dosage schedule, elderly (G) 284; pharmacokinet- Controlled Substances Act, cancer patients (A) 1229 Emergency Medicine (J.P. Ornato, E.R. Gonzalez), 216; Early ics, elderly (G) 285; postantibiotic effect (A) 156; resistance, Core MEDLINE, compared with EMBASE, TOXLINE, MED- Phase Drug Evaluation in Man (J.O. Grady, O.1. Linet), 1275; Pseudomonas aeruginosa (L) 871; thrombocytopenia (SR) LINE, BIOSIS, IDIS, PASCAL, PHARMLINE, IPA, adverse Effects of Drugs on Clinical Laboratory Tests, 3rd Edition 135 drug reactions (RPR) 1062 (D.S. Young), 1017; Generic Drugs: A Guide to FDA Ap- Ceftizoxime, pharmacokinetics, neonates, infants (RPR) 344 Corrections, see Letters proval Requirements, 2nd Edition (D.O. Beers), 879; Good- Ceftriaxone, conversion to aminoglycoside, cost (L) 319; Corticosteroids, see Steroids, cortico- man and Gilman's The Pharmacological Basis of Therapeu- ingitis (SR) 27; p ibiotic effe(Ac) t156 ; Cortisone acetate, asthma (PA) 72 tics, 8th Edition (A.G. Gilman, T.W. Rall, A.S. Nies, P. stability, peritoneal dialysis (SR) 741; thrombocytopenia (SR) Costs, see Pharmacoeconomics Taylor), 1401; Handbook of Nonprescription Drugs, 9th Edi- 135; utilization (L) 872 Council on Student Affairs, see Association News (NC) tion, 322; Handbook on Injectable Drugs, 6th Edition (L.A. Cefuroxime, prophylaxis, coronary bypass surgery (TC) 481 Covington, Timothy R., pharmaceutical editor, Handbook of Trissel), 1144; Handbook of Pharmacy Health-Care: Diseases Cefuroxime axetil, suspension, pediatrics (PED) 1236 Nonprescription Drugs (NC) 1431 and Patient Advice (R.J. Harman), 1402; Infections in Intra- Cephalosporins, ibiotic effe(Ac) t15 4 Critical Care Therapeutics, Charge and Reimbursement Anal- venous Drug Abusers (D.P. Levine, J.D. Sobel), 1401; Infec- Cephalothin, postantibiotic effect (A) 156 ysis for Intensive Care Unit Patients in a Large Tertiary tious Diseases: Prophylaxis & Chemotherapy (J. Schneider, J. Cerebral blood flow, dynamic, enalapril, prazosin (RPR) 1299 Teaching Hospital, 1231; Is There a Reliable Index of Hugher, H. Henderson), 878; Inside the Drug Industry (B. Charcoal, activated, acetylcysteine absorption (TC) 1081, phar- Glomerular Filtration Rate in Critically Ill Patients?, 169; Par- Spilker, P. Cuatrecasas), 683; Medical Informatics: Computer macokinetics, phenytoin poisoning (PED) 646 enteral Nutrient Admixtures as Drug Vehicles: Theory and Applications in Health Care (E.H. Shortliffe, L.E. Perreault), Chloramphenicol, postantibiotic effect (A) 154 Practice in the Critical Setting, 276 105; Oral Controlled Release Products: Therapeutic and Bio- Chlordiazepexide, alcohol withdrawal (DIAS) 31; compared Cromolyn sodium, asthma, review (PA) 998 pharmaceutic Assessment (E.Gundert-Remy, H. Moller), 216; with prop lol, alcohol withd 1 (DIAS) 32 Curare, pharmacodynamics (A) 57; pharmacokinetics (A) 58 Patient Compliance in Medical Practice and Clinical Trials Chlormezanone, fixed drug eruption (SR) 604 Cyclophosphamide, myasthenia gravis (A) 1105 (J.A. Cramer, B. Spilker), 1144; Pediatric Drug Formulations Cholecalciferol, psoriasis, review (A) 835 Cyclosporine, clearance, kidney failure (A) 1219;Graves’oph- (M.C. Nahata, T.F. Hipple), 104; Percutaneous Antirheumatic Cholera, incidence (NC) 1294 thalmopathy (DIAS) 750; interaction, erythromycin (DIAS) Therapy: A Reappraisal (K. Brune), 217; Pharmacy: An Illus- Cholestyramine, compared with simvastatin (FF) 260 30; myasthenia gravis (A) 1 106; no interaction, acyclovir (L) trated History (D.L. Cowen, W.H. Helfand), 683; Principles Cholinergic antagonists, asthma (PA) 998 316; pharmacokinetics, plasmapheresis (L) 211 of Drug Action: The Basis of Pharmacology, 3rd. Edition Cholinesterase inhibitors, myasthenia gravis (A) 1103 Cystic fibrosis, amiloride, lung disease (DIAS) 1340; colistin, (W.B. Pratt, P. Taylor), 216; Syllabus for the Review Course Cilastatin, with imipenem, drug usage evaluation (RPR) 348, toxicity (RPR) 1168; infection, home monitoring (A) 840; in Addiction Medicine (B.B. Wilford), 878; Testing and Eval- (L) 1399; seizures (CR) 351 pancreatic enzymes, prescription drugs (NC) 1157; theo- uation of Drugs of Abuse (M.W. Adler, A. Cowan), 322 Cilazapril, clearance, kidney failure (A) 1220 phylline clearance (L) 212 Textbook of Secretory Diarrhea (E. Leventhal, M.E. Duffey), Cimetidine, epidural morphine pruritus (RPR) 716; idiopathic Cytochrome P-450, phenytoin biotransformation (PED) 989 1275; The New Generation of Quinolones (C. Siporin, C.L. urticaria (DIAS) 609 Cytomegalovirus, foscarnet sodium, review (FF) 41 Heifetz, J.M. Domagala), 560; Treatment of Chronic Pain: Ciprofloxacin, interaction, antacids, review (DIAS) 473, cations Possibilities, Limitations and Long-term Follow-up, 439 (DIR) 1250, sucralfate (RPR) 578, theophylline, computer Books Received, 106, 217, 324, 440, 561, 684, 879, 1018, 1145, monitoring (L) 1011, warfarin (L) 1397; mycobacterial infec- 1276, 1402 tions (RPR) 919; oral, compared with parenteral antibiotics D Brachial plexus palsy, geriatric chair, haloperidol (SR) 1072 (PEP) 857; pharmacokinetics, bacterial susceptibility (RPR) Bradycardia, acetylcholine, intraocular (CR) 1178; nimodipine 1050 (CR) 247 Citrobacter freundii, meningitis, neonates, ceftriaxone (SR) 27 Bretylium, pediatric cardiopulmonary resuscitation (TC) 768 Clayton, Anne G., AACP Lyman Award (NC) 572 Dapsone, compared with clofazimine (FF) 527 Bromocriptine, cocaine abuse (A) 820; compared with selegi- Clearance, see Excretion Databases, adverse drug reactions, comparison (RPR) 1062 line, Parkinson’s disease (FF) 38 Clindamycin, hypersensitivity (L) 317; postantibiotic effect (A) Delirium, misoprostol (SR) 133 Bronchodilators, review (PA) 997 154 Dependence, cancer patients (A) | 226; codeine, recovering al- Bufuralol, clearance, kidney failure (A) 1215 Clinical studies, altretamine (FF) 147; anticonvulsants (A) 979; coholic, addict (A) 49 Bulimia, fluoxetine (DIAS) 254 capsaicin (FF) 384; clofazimine (FF) 526; dipyridamole (FF) Depression, tricyclic antidepressants, Parkinson's disease Bupropion, attention deficit disorder with hyperactivity (DSP) 1087; ES monoclonal antibody (FF) 786; felodipine (FF) (DIAS) 137 1209 1196; fludarabine (FF) 520; foscarnet (FF) 43; goserelin ac- Desipramine, attention deficit disorder with hyperactivity (DSP) Butofilolol, clearance, kidney failure (A) 1216 etate (FF) 798; human monoclonal antibody (FF) 780; idaru- 1209; cocaine abuse (A) 818; pharmacokinetics (TM) 1368 bicin (FF) 507; immune globulin (DSP) 809, (DSP) 810; keto- Desmethyldiazepam, clearance, kidney failure (A) 1217 conazole (A) 395; ine (FF) 141; ond (FF) Dexamethasone, bacterial meningitis, infants, children (PED) 370; pegademase bovine (FF) 1094; pravastatin (FF) 390; 543; compared with hydrocortisone, betamethasone, asthma C quinapril (FF) 500; selegiline (FF) 36; sertraline (FF) 954; (PA) 73; compatibility, ondansetron (L) 869 simvastatin (FF) 259; vitamin D (A) 836 Dextran, HIV inhibition (DIAS) 606 Clofazimine, adverse reactions (FF) 529; compared with dap- Dextroamphetamine, attention deficit disorder with hyperactiv- sone (FF) 527; interaction, isoniazid, review (FF) 530; phar- ity (DSP) 1209; compared with imipramine, attention deficit Caffeine, interaction, phenothiazine (L) 437 macokinetics (FF) 526; pharmacology (FF) 525; review (FF) disorder with hyperactivity (DSP) 1207 Caffeine sodium benzoate, electroconvulsive therapy (DIAS) Dextrose, 5%, amphotericin B/ sulfate c r J 1079 Clomipramine, attention deficit disorder with hyperactivity (RPR) 123 Calcifediol, psoriasis (A) 835 (DSP) 1209 Diabetes, foot infections, home care (A) 846 Calcitonin, migraine (DIAS) 1185 Clonazepam, mania (SR) 938 Dialysis, —— ceftriaxone sodium stability (SR) 741 Calcitriol, psoriasis (A) 835 Clonidine, growth acceleration (DIAS) 1339, (E) 1384 DIAS Rounds,A sine in icular Tachycardia, Calcium, interaction, quinolones (DIR) 1252; pediatric car- Clorgiline, atiention deficit disorder with hyperactivity (DSP) 749, Adverse Effects of Sustained- Release Niacin, 253; Al- diopulmonary resuscitation (TC) 766 1209 prostadil in Impotence, 363; Amiloride for Lung Disease in DICP, The Annals of Pharmacotherapy = 199] December, Volume25 # 1433 Cystic Fibrosis, 1340; Aseptic Meningitis and Muromonab- ciprofloxacin—sucralfate (RPR) 578 pruritus, cimetidine (RPR) 716; muromonab-CD3, aseptic CD3 Therapy, 138; Caffeine in Electroconvulsive Therapy, ciprofloxacin—warfarin (L) 1397 meningitis (DIAS) 138, (L) 1395; naproxen, aseptic meningi- 1079; Calcitonin in Migraine, 1185; Calcium Carbonate in clofazimine-isoniazid, review (FF) 530 tis (SR) 1183; niacin, sustained-release, hep icity (L) Hyperphosph 945; Cimetidine in Idiopathic Urticaria, cyclosporine—acyclovir, none (L) 316 1014, review (DIAS) 253; nifedipine, hypertension (L) 99; ni- 609; Clonidine for Growth Acceleration, 1339; Cyclosporine cyclosporine—erythromycin (DIAS) 30 modipine, bradycardia (CR) 247; ondansetron, review (FF) in Graves’ Ophthalmopathy, 750; Dep Treatment in digoxin-sucralfate (SR) 745 377; pegademase bovine, review (FF) 1094; pentamidine, Parkinson's Disease, 137; Dextran Inhibition of Human Im- erythromycin—cyclosporine (DIAS) 30 nephrotoxicity, hyperkalemia, AIDS (RPR) 1171; pentoxi- munodeficiency Virus, 606; Dipyridamole in Angioplasty, erythromycin—felodipine (L) 1007 fylline, gastrointestinal bleeding (L) 315; phenothiazine, ap- 747; Erythromycin and Cyclosporine Drug Interaction, 30; felodipine—erythromycin (L) 1007 nea (CR) 244; phenytoin, hypersensitivity (CR) 929; placebo, Fluoxetine and Suicidal Ideation, 607; Fluoxetine in Bulimia, felodipine, review (FF) 1202 hypervagotonia (SR) 471; pravastatin, review (FF) 392; pro- 254; Granulocyte-Macrophage Colony-Stimulating Factor in fluoxetine—imipramine (L) 1273 cainamide, myopathy (L) 436, pseudo-obstruction (SR) 1334; Neutropenia, 32; history (SC) 306; Ketamine and Succinyl- fluoxetine, review (DIR) 657 quinapril, review (FF) 502; rifampin, acute hemolysis, renal choline for Emergency Intubation of Pediatric Patients, 475; imipramine—fluoxetine (L) 1273 failure (SR) 743; roxithromycin, pancreatitis (L) 1137; sertra- Midazolam Routes of Administration, 476; Niacinamide for indomethacin—phenylpropanolamine, none (RPR) 234 line, review (FF) 957; simvastatin, review (FF) 261; sympa- Bullous Pemphigoid, 1187; Phosphate Binders in Hyperphos- isoniazid—clofazimine, review (FF) 530 tholytic agents, review (DSP) 969; tetanus toxoid, anaphylaxis phatemia of Chronic Renal Failure, 942; Significance of the lisinopril—lithium (L) 101 (L) 870; thiethylperazine, neuroleptic malignant syndrome (L) Ciprofloxacin—Antacid Interaction, 473; Talc in the Treatment lithium-lisinopril (L) 101 1007; triazolam, market removal (E) 1263; trimethobenza- of Malignant Pleural Effusion, 1187; Topical Aspirin for Post- mexiletine-theophylline (RPR) 727 mide, neuroleptic malignant syndrome (L) 1007; vancomycin, herpetic Neuralgia, 1077; Topical Uses of Testosterone, 1341; nafcillin-warfarin (CR) 598 peritonitis (SR) 602, rash (CR) 1326; vitamin Kj, anaphylaxis Trimethoprim/Sulfamethoxazole Concentrations in Pneumo- pegademase bovine—pentostatin, review (FF) 1094 (L) 871 cystis carinii Pneumonia, 941; Verapamil as Migraine Pro- pegademase bovine—vidarabine, review (FF) 1094 Drugs, generic, product distrust (RC) 430 phylaxis, 1076; Verapamil in Premenstrual Syndrome, 361; pentostatin—-pegademase bovine, review (FF) 1094 Vitamin D in Psoriasis, 753; Vitamin E as an Anticonvulsant, phenothiazine—caffeine (L) 437 362 phenylpropanolamine—indomethacin, none (RPR) 234 Diazepam, alcohol withdrawal (DIAS) 31 phenytoin-tizanidine (L) 1273 E Dicloxacillin, postantibiotic effect (A) 155 piperacillin-tobramycin (SR) 357 DICP, The Annals of Pharmacotherapy, 2Sth anniversary (E) pravastatin, review (FF) 392 97; Francke, Donald E., biographical sketch (SC) 425; history, quinidine—sucralfate (SR) 745 DIAS Rounds (SC) 307; pediatric information, review articles quinolones—cations, review (DIR) 1249 Economics, ciprofloxacin, 0: al, compared with parenteral antibi- (L) 559 quinolones—theophylline, meta-analysis (DIR) 191 otics (PEP) 857 Diethylstilbestrol, compared with goserelin acetate (FF) 799 ranitidine—theophylline (CR) 21, (L) 1139 Edetate calcium disodium, lead intoxication (CR) 932 Digoxin, concentrations, compliance (L) 103, with digoxin im- sertraline, review (FF) 958 Editorials, see also, An Opinion; Bosso, John A., Academic mune Fab (RPR) 1047; congestive heart failure (L) 320, re- sucralfate—ciprofloxacin (RPR) 578 Pharmacy Practice and Research, 1129; Gal, Peter, James, view (A) 1350; dissociation, digoxin immune antibody, kid- sucralfate—digoxin (SR) 745 Cathe, Reed, Michael D., Indomethacin Therapy for Intra- ney failure (L) 1269; Lanoxin vs. Lanoxicaps (RPR) 1043; sucralfate—quinidine (SR) 745 ventricular Hemorrhage in Neonates: Another Use for that with quinidine/warfarin, interaction, sucralfate (SR) 745 sucralfate—warfarin (SR) 745 “Old” Drug, 1385; Kelly, H. William, Asthma, Aerosols, and Digoxin immune Fab, digoxin assay anomalies (SR) 739; theophylline—mexiletine (RPR) 727 Patient Ecucation, 668; Nahata, Milap C., Research Produc- digoxin concentrations (RPR) 1047; digoxin dissociation, kid- theophylline—quinolones, meta-analysis (DIR) 191 tivity and Funding, 669; Perry, Paul J., Smith, Daniel A., ney failure (L) 1269; pharmacokinetics, kidney failure (CR) theophylline-ranitidine (CR) 21, (L) 1139 Triazolam—The Never-Ending Story, 1263; Usala, Anton- 1315 tizanidine—phenytoin (L) 1273 Lewis, Reed, Michael D., Clonidine Therapy for Short 5°,5’-Dihydrofolic acid reductase, phenytoin biotransformation tobramycin-piperacillin (SR) 357 Stature: Can the Question be Put to Rest?, 1384; Whitney, (PED) 989 vidarabine—pegademase bovine, review (FF) 1094 Harvey A.K., Jr., Reborn at Age 25, 97 Dilevaiol, beta-adrenergic receptor response, racial groups (A) warfarin-ciprofloxacin (L) 1397 Edrophonium chloride, myasthenia gravis (A) 1103 827 warfarin—nafcillin (CR) 598 Education, continuing, medical vs. pharmaceutical (SR) 1336; Diphenhydramine, toxicity, varicella zoster (CR) 130 warfarin-sucralfate (SR) 745 pharmacy, B.S. vs. Pharm.D. degree (SC) 94, (L) 679, (L) Dipyridamole, compared with aspirin, angioplasty (DIAS) 747; Drug Interactions and Reactions Update, Adverse Effects and 1400, Canadian Pharm.D. program (NC) 1158, changes in pharmacodynamics (FF) 1086; pharmacokinetics (FF) 1086; Drug Interactions Associated with Fluoxetine Therapy, 657 practice (O) 431, quality (RC) 1133, research, importance (E) review (FF) 1085 Meta-Analysis of Quinolone-Theophylline Interactions, 191 1129, Zimbabwe (IR) 302; physician, residencies, prescription Diuretics, congestive heart failure, review (A) 1350; potassium- Quinolone—Cation Interactions: A Review, 1249 writing (RPR) 17 sparing vs. potassium supplements (L) 439 Drug Selection Perspectives, Around the Beta-Blockers, One Education and Research News (NC), Applications Invited for Dobutamine, congestive heart failure, review (A) 1352; pedi- More Time, 962; Clinical Use of Biologic Response Modifiers AIHP Grants, 1293; Campbell University Receives Maximum atric cardiopulmonary resuscitation (TC) 767 in Cancer Treatment: An Overview. Part II. Colony-Stimulat- Accreditation, 1158; First Canadian Pharm.D. Program, 1158; Dopamine, pediatric cardiopulmonary resuscitation (TC) 767 ing Factors and Interleukin-2, 490; Treatment of Attention First Chair in Geriatric Pharmacotherapy, 226; New Rho Dosage, aminoglycosides, pharmacokinetics, two- vs. three- Deficit Hyperactivity Disorder: A Critical Review, 1207; Use Chi-AFPE-Merck Scholarship, 1293 point method (L.) 1141; corticosteroids, asthma (PA) 77; of Intravenous Immune Globulin Therapy: An Overview, 805 Educational Events, 6, 223, 332, 440, 561, 697, 881, 1030, epinephrine, cardiopulmonary resuscitation (TC) 773; fre- Drug utilization, albumin, physician intervention (RPR) 239; 1154, 1289, 1418 quency, antibiotics, cost (PEC) 546; isosorbide dinitrate (L) antibiotics, Spain (IR) 662; ceftriaxone (L) 872; estrogens Edwards, David J., Wayne State University Career Develop- 1272; theophylline, pediatrics (PED) 179; tranyicypromine (PEP) 418; histamine2-receptor antagonists (L) 681; human ment Chair Award (NC) 1038 sulfate, MAO inhibition (L) 99 immunodeficiency virus (PEP) 1374; imipenem/cilastatin (L) Electroconvulsive therapy, caffeine sodium benzoate (DIAS) Dosage form, endotracheal, pediatric cardiopulmonary resusci- 1399; ketorolac, formulary restriction (L) 1399: neuroleptic 1079 tation (TC) 761; epidural, morphine, pruritus (RPR) 716; ex- agents, Italy (PEP) 296; nicotine gum (RPR) 730 EMBASE, compared with TOXLINE, MEDLINE, BIOSIS, tended-release tablets, gastric obstruction (L) 678; gel, com- Drug withdrawal, beta-blockers (DIAS) 31 IDIS, Core MEDLINE, PASCAL, PHARMALINE, IPA, ad- pared with suppository, prostaglandin E, (RPR) 456; gum, Drugs, availability, nifedipine, sustained-release (L) 317 verse drug reactions (RPR) 1062 nicotine (RPR) 730; inhalers, metered-dose (PA) 638; i Drugs, adverse reactions, acetylcholine, intraocular, hypoten- Emergency services, India (IR) 424 traocular, acetylcholine (CR) 1178; intraosseous, pediatric sion, bradycardia (CR) 1178; altretamine, review (FF) 150; Emswiller, Carl F. Jr., president-elect, American College of cardiopulmonary resuscitation (TC) 762; intraperitoneal, amantadine, neurotoxicity, renal transplant (CR) 1175; am- Apothecaries (NC) 1431 vancomycin (SR) 602; intravenous, compared with intramus- photericin B, hepatotoxicity (L) 559; aztreonam, myelosup- Enalapril, agranulocytosis (CR) 461; compared with quinapril cular, teicoplanin (RPR) 914, conversion to oral, ranitidine pression (CR) 594; Bacillus Calmette-Guerin, review (A) (FF) 501; congestive heart failure, review (A) 1351; psychosis (SR) 251, dipyridamole (FF) 1085, enalaprilat (SR) 25; nebu- 1361; bezafibrate, rhabdomyolysis (L) 869; capsaicin, review (L) 558; vasodilatory stimulus, dynamic cerebral blood flow lized, ventilator parameters, neonates (PED) 272; oral, (FF) 385; ceftazidime, thrombocytopenia (SR) 135; ceftriax- (RPR) 1299 ciprofloxacin, compared with parenteral antibiotics (PEP) one, thrombocytopenia (SR) 135; chlormezanone, fixed drug Enalaprilat, intravenous, hypertension (SR) 25 857, conversion to intramuscular depot, formulation (L) 1270; eruption (SR) 604; cilastatin, with imipenem, seizures (CR) Encainide, clearance, kidney failure (A) 1216; marketing dis- parenteral, conversion to oral, Hj-receptor antagonist (PEC) 351; clofazimine, review (FF) 529; clonazepam, mania (SR) continued (NC) 1294 80; suspension, cefuroxime axetil, pediatrics (PED) 1236; 938; database comparison (RPR) 1062; ES monoclonal anti- Endocarditis, home care (A) 845; prophylaxis, erythromycin sustained-release, niacin, adverse reactions (DIAS) 253, (L) body, review (FF) 788; enalapril, agranulocytosis (CR) 461, (L) 1396 1014; tablets, digoxin, compared with capsules (RPR) 1043; psychosis (L) 558; erythromycin, agranulocytosis (L) 1136; Endomyometritis, postpartum, gentamicin pharmacokinetics topical, aspirin, postherpetic 1 uralgia (DIAS) 1077, testos- extended-release tablets, gastric obstruction (L) 678; famoti- (RPR) 1306 terone (DIAS) 1341 dine, arrhythmia (L) 315, thrombocytopenia (L) 678; felodi- Endotoxin, human monoclonal antibody, review (FF) 778 Dosage schedule, aminoglycosides (L) 558; ceftazidime, elderly pine, review (FF) 1202; fluorouracil, local tissue reaction (SR) Enoxacin, interaction, cations (DIR) 1250 (G) 284; plicamycin (L) 215 249; fluoxetine, glaucoma (L) 436, mania (L) 1395, review Eosinophilia—myalgia syndrome, tryptophan, epidemiology Doxepin, pharmacokinetics (TM) 1368 (DIR) 657, suicidal ideation (DIAS) 607; flurbiprofen, renal (PEP) 1259 Doxorubicin, superficial bladder cancer (A) 1357 papillary necrosis (L) 870; flutamide, methemoglobinemia Ephedrine, hypertensive crisis (CR) 1068 Drug abuse, cocaine, treatment, review (A) 818 (SR) 600; foscarnet sodium, review (FF) 44; goserelin acetate, Epinephrine, dosage, cardiopulmonary resuscitation (TC) 773; Drug administration, antibiotics, cost (PEC) 546; delay, throm- review (FF) 800; hepatitis B vaccines, review (A) 624, (A) pediatric cardiopulmonary resuscitation (TC) 762 bolytic agents, myocardial infarction (A) 1096; hepatitis B 631; human monoclonal antibody, review (FF) 781; im- Epoxide hydrolase, phenytoin biotransformation (PED) 989 vaccine (A) 628; human growth hormone, Nordiject (RPR) ipenem, with cilastatin, seizures (CR) 351; immune globulin, Equipment, finger oscillometric blood pressure device (RPR) 585; intravenous, methylprednisolone acetate (L) 436; mida- review (DSP) 812; interferon alfa-2a, impotence (L) 1397; 1310; heparin lock, necessity (A) 399; inhalers, metered-dose, zolam (DIAS) 476; parenteral nutrition, review (CC) 276 ipratropium bromide, urinary retention (SR) 939; isoniazid, drug delivery (PA) 638, patient education (E) 668; mechanical Drug information, adverse drug reactions, database comparison peripheral neuropathy (L) 100; ketoconazole, hepatotoxicity ventilators, home care (A) 843, parameters, nebulized drugs, (RPR) 1062; elderly (G) 410; impact on prescribing practices (CR) 1321, review (A) 397; leucovorin, local tissue reaction neonates (PED) 272; Nordiject, human growth hormone (L) 102; manual vs. computer-based literature search (L) 214, (SR) 249; lisinopril, hyponatremia (L) 873; literature search, (RPR) 585 (L) 875; package inserts, Belgium (IR) 1002; penicillin, out- manual vs. computer (L) 875; lithium, leukemia (TC) 948; Errors, medication, acetohexamide, acetazolamide mix-up (L) patients (RPR) 925; Zimbabwe, establishment (IR) 1379 lorazepam, maternal, neonatal feeding difficulties, muscle 100, France (PEP) 1113; prescribing, prevention (O) 1388 Drug interactions, acyclovir-cyclosporine, none (L) 316 tone disorders (L) 1137; meperidine, taste alteration (L) 1137; Erythromycin, agranulocytosis (L) 1136; clearance, kidney fail- antacids—ciprofloxacin, review (DIAS) 473 mesalamine, review (FF) 143; mesna, hypertension (L) 867; ure (A) 1217; interaction, cyclosporine (DIAS) 30, felodipine beta-lactams, synergy (A) 972 methyldopa, granulomatous hepatitis (L) 1269; metoclo- (L) 1007; postantibiotic effect (A) 154; prophylaxis, endo- caffeine—phenothiazine (L) 437 pramide, urinary retention (SR) 469; mexiletine, pulmonary carditis (L) 1396 cations—quinolones, review (DIR) 1249 fibrosis (SR) 1329; misoprostol, delirium (SR) 133; molin- Esmolol, intravenous, acute aortic dissection (CR) 735; pharma- ciprofloxacin—antacids, review (DIAS) 473 done, neuroleptic malignant syndrome (SR) 1071; morphine, cokinetics (DSP) 965; pharmacology (DSP) 962 1434 = DICP,The Annals of Pharmacotherapy ® 199] December, Volume 25 Estrogens, drug utilization (PEP) 418 Gemfibrozil, comoared with simvastatin (FF) 260 Hyponatremia, lisinopril (L) 873 Ethics, marketing (L) 1138 General News (NC), Canthaxanthin: DICP Valuable in Aplastic Hypotension, acetylcholine, intraocular (CR) 1178 Europe, AIDS, incidence (NC) 114 Anemia Case, 701; DICP Appoints Two Editors, 1037; Model Excretion, carbamazepine, children (PED) 1109; glomerular fil- Standards (3rd Ed) Now Available, 1431; Pancreatic Enzyme tration rate, index (CC) 169; hepatic, effect of kidney failure Products, 1157; Use of Encainide and Moricizine Halted, (A) 1214; hydroxychloroquine, rheumatoid arthritis (RPR) 1294 I-K 1302; theophylline, cystic fibrosis (L) 212 Gentamicin, pharmacokinetics, postpartum endomyometritis (RPR) 1306; postantibiotic effect (A) 156; removal, hemofil- tration (CR) 127 Geriatrics, ceftazidime, dosing schedule (G) 284; digoxin con- Idarubicin, pharmacokinetics (FF) 506; pharmacology (FF) F cmeanttiroant io(nGs), 4L1a0;n oxhianl opvesr.i dLoaln,o xgiecriaaptsr ic( RcPhaRi)r , 1b0r4a3c;h iadlr ugp leinxfuosr - Imi50p6e;n erme,vi epwo st(aFnFt)i b5i0o5t;i c toexfifceictty ((AF)F ) 15541;2 with cilastatin, drug palsy (SR) 1072; prescribing patterns, ambulatory care (G) usage evaluation (RPR) 348, (L) 1399; seizures (CR) 351 186; tuberculosis, review (G) 650 Imipramine, cocaine abuse (A) 819; compared with dextroam- Famotidine, arrhythmia (L) 315; thrombocytopenia (L) 678 Geriatrics and Gerontology, Ceftazidime in the Elderly: Ap- phetamine, attention deficit disorder with hyperactivity (DSP) FDA News (NC), FDA Toll-Free Line for Health Professionals, propriateness of Twice-Daily Dosing, 284; Perceived Purpose 1207; interaction, fluoxetine (L) 1273 1293 of Prescription Drugs: The lowa 65+ Rural Health Study, 410; Immune system, review (DSP) 805 Federation Internationale Pharmaceutique, see Association Prescribing Patterns for Older Heavy Drug Users Living in the Immunoassay, digoxin, anomalies (SR) 739 News (NC) Community, 186; Tuberculosis in the Elderly: Incidence, Immunoglobulin, myasthenia gravis (A) 1106; synthesis, Felbamate, pharmacokinetics (A) 979; review (A) 980 Manifestations, PPD Skin Tests, and Preventive Therapy, 650 schizophyllan, Staphylococcus aureus (L) 101 Fellowships and Residencies, California, University of Cali- Glaucoma, fluoxetine (L) 436 Immunosuppressive agents, myasthenia gravis (A) 1 105 fornia, San Francisco, 1418, University of Southern Califor- Globulin, immune, A, E, D, G, M, review (DSP) 805; adverse Impotence, alprostadil (DIAS) 362; interferon alfa-2a (L) 1397 nia, 1285; Connecticut, Hartford Hospital, 1417; Idaho, Ida- reactions, review (DSP) 812; compared with corticosteroids Incompatibility, amphotericin B, magnesium sulfate (RPR) ho State University, 1417; Maryland, Center for Drug (DSP) 809; idiopathic thrombocytopenic purpura, review 123; ondansetron, dexamethasone (L) 869 Evaluation and Research, Food and Drug Administration, 109, (DSP) 808; pharmacokinetics (DSP) 807 India, emergency services (IR) 424 Maryland Poison Center, Michigan, University of Glomerular filtration, index, critical care (CC) 169 Indomethacin, neonatal intraventricular hemorrhage (TC) 1344, Michigan, 1285; Missouri, Marion Merrell Dow, 446, Quincy Glucose, biochemical marker, nutrition support (A) 265 (E) 1385; no interaction, phenylpropanolamine (RPR) 234 Research Center, 110, University of Missouri-Kansas City, Glucose-6-phosphate dehydrogenase, deficiency, aspirin (SR) Industry, pharmaceutical, US, abroad (RC) 427 1417; Nebraska, St. Joseph Hospital, 1417; New York, Al- 1074 Infections, monitoring, outpatients (A) 840; mycobacterial, bany College of Pharmacy, 1417; Texas, University of Texas Glutathione-S-transferase, phenytoin biotransformation (PED) ciprofloxacin (RPR) 919; skin, soft-tissue, teicoplanin (RPR) oHfe aUlttahh ,S c1i2e8n5c e Center at San Antonio, 109; Utah, University Gol9d8,8 asthma, review (PA) 999 Inhalers, metered-dose, instructions (L) 321 Felodipine, adverse reactions (FF) 1202; compared with amil- Goserelin acetate, adverse reactions (FF) 800; compared with Insulin, admixture, parenteral nutrition (CC) 280 oride (FF) 1198; compared with hydralazine (FF) 1199; com- diethy|stilbestrol (FF) 799; pharmacodynamics (FF) 797; Intensive care units, charge, reimbursement (CC) 1231 pared with hydrochlorothiazide (FF) 1198; compared with pharmacokinetics (FF) 797; pharmacology (FF) 796; prostate Interferon alfa-2a, impotence (L) 1397 metoprolol (FF) 1198; compared with nifedipine (FF) 1199; cancer, review (FF) 796 Interleukin-2, cancer (DSP) 490; pharmacokinetics (DSP) 493; compared with prazosin (re) 1199; compared with propran- Granulocyte-macrophage colony-stimulating factor, neu- review (DSP) 490; toxicity (DSP) 494 olol (FF) 1199; interaction, erythromycin (L) 1007; interac- tropenia (DIAS) 32 International normalized ratio, warfarin, interlaboratory ef- tions, review (FF) 1202; pharmacokinetics (FF) 1195; phar- Graves, Nina M., Fellow, ACCP (NC) 1038 fects (TC) 1190 macology (FF) 1193; review (FF) 1193 Green, Melvin W., obituary (NC) 1294 International Pharmaceutical Abstracts, compared with EM- Fentanyl, labeling (L) 1011 Growth, acceleration, clonidine (DIAS) 1339, (E) 1384 BASE, TOXLINE, MEDLINE, BIOSIS, IDIS, Core MED- Fetal hydantoin syndrome, phenytoin biotransformation (PED) Growth hormone, human, Nordiject delivery system (RPR) 585 LINE, PASCAL, PHARMLINE, adverse drug reactions 987 (RPR) 1062 Filtration, hemo, gentamicin, vancomycin removal (CR) 127 International Reports, Attitude of the Public Toward Technical Finley, Rebecca S., board of directors, American Society of Package Inserts for Medication Information in Belgium, 1002; FleHcoasipniitdael, Pclheaarramncae,c iksi(dtNnseCy ) f1a4i3l1u re (A) 1219 H CLaobmeplairnagt,i v8e6 3;S tEumdye rgoef nScayu diH-eMaaltrhkceatreed inP rIondduicat, s 42a4n;d PUrSe scDrirbu-g Fluconazole, compared with clotrimazole, vulvovaginal can- ing Patterns in Saudi Arabia, 90; Recommendations for Estab- didiasis (RPR) 582 lishing a Drug and Toxicology Information Center in a Devel- Fludarabine, pharmacokinetics (FF) 519; review (FF) 518; toxi- Haloperidol, geriatric chair, brachial plexus palsy (SR) 1072; oping Country, 1379; The Profession of Pharmacy in FFlluucooirrt yo u(rFaFc)ii nlo5,l2 2l ocal steies suQeu irneoaclt ion (SR) 249 HHaarlotro,atl h Latino nei,dm a hdeLep.pa,ot itUt iScsPo, Cnv ceordlsrciuhoginc ,iin neff oor(rLmm)au tl2ia1ot1ni ond ev(Le)l o1p2m7e0n t programs IntCZuaibrmaebt,ai ob6nw6,2e ,c hi3l0d2r;e nU,s ek eotfa mRienset/rsicutcecdi nyAnltcihboiloitniec s i(nD IAPSr)i ma4r7y5 Flu(oDxIeAtSi)ne ,2 54a;d vegrlsaeu croemaact i(oLn)s , 43r6e;v iienwt er(aDcItRi)o n,6 57i;m ipburlaimmiinae (L) Hea(lNtCh)c a4r5e0, home, monitoring infections (A) 840; practice, lToowwaa, Drruruagl hIenaflothr msattuidoyn, dSreurgv icien,f orcmoamtpioanr,e de ldweirtlhy E(MG)B A4S1E0 , 1273; interactions, review (DIR) 657; mania (L) 1395; suici- competence (O) 205 TOXLINE, MEDLINE, BIOSIS, Core MEDLINE, PASCAL, FFlluudrpalbe iniptdrheoiafxteoinlon, d(reDecnIaaAnlSo )ap taep6i,0l 7l acroyc ainneec roasbiuss e( L()A )8 7802 1 HHeeaa4rr0tt8 dfaiisleuarsee,, ccoonnggeesntiitvale,, amlapnroasgteamdieln,t ,n eorneavtiaelw t(rAa)ns p1o3rt4 9 (PED) IprPtaiHotnAr oR(pSMiRLu)I m,N9 3E9a, s thImPaA,, raedvvieerws e (PdAr)u g 99r8e;a ctbiroonmsi d(eR,P Ru)r in1a0r6y 2 reten- Flutamide, methemoglobinemia (SR) 600 Hemofiltration, see Filtration, hemo Iron, interaction, quinolones (DIR) 1253 Folic acid, neural tube defects (NC) 1158; phenytoin biotrans- Hemorrhage, neonatal intraventricular, indomethacin (TC) I-Scrub, blepharitis (SR) 359 Forfmorumlaatriyon F(oPrEuDm), 9A8l9t retamine, 146; Clofazimine: A Review Hep1a3r4i4n, , (Ea)c ut1e3 85m yocardial infarction (TC) 613; admixture, par- Isonneiuarzoidp,a thiyn te(rLa)c ti1o0n0, clofazimine, review (FF) 530; peripheral of Its Use in Leprosy and Mycobacterium avium Complex In- enteral nutrition (CC) 279; neonatal thrombosis (PED) 853; Isosorbide dinitrate, dosing, tolerance (L) 1272 fection, 525; ES Monoclonal Immunoglobulin M Antibody for therapy institution, deep vein thrombosis (L) 1397 Isradipine, clearance, kidney failure (A) 1218 Ntheew T rDeiahtymdernotp yorfi dGirnaem -CNaelgcaituimv-eC hSaenpnseisl, A7n84t;a goFneilsotd,i pi1n1e9:3 ; A Hepcaotlicthiisc,i neg ra(nLu) lo21m1a tous, methyldopa (L) 1269; halothane, JIotailnyt, Cnoeumrmoilespstiioc n droufg Puhtialrimzaatcioyn (PPrEaPct)i t2i9o6n ers, see Associa- Fludarabine: A Review, 518; Foscarnet Sodium, 41; Goserelin Hepatitis B, transmission prevention (NC) 1157 tion News (NC) Acetate Implant: A Depot Luteinizing Hormone-Releasing Hepatitis B vaccines, adverse reactions (A) 624, (A) 631; intra- Joint C on Accred of Healthcare Organiza- Hormone Analog for Advanced Prostate Cancer, 796; Human dermal (A) 628; utilization (O) 671; yeast-derived, review (A) tions, outcome criteria (O) 205 Monoclonal Antibody Against Endotoxin, 778; Idarubicin: A 617 Kaul, Alan F., president, Health Outcomes Management, Ltd. dSaemcoolned:- GeUnseer aitn iTohna llAonutsh raCchylcolriindee, TI5 052;0 1 InSttrreasvse noIumsa giDnigp,y ri- HHeipsattaomtionxei,c-irtye,c epatmophro taenrtiacgionn iBs t(sL,) a5d5m9;i xtkuerteo,c onpaazroelntee r(alC R)n utr1i3-2 1 Kel(lNyC, ) Wi1l4l3i1 am N., board of directors, American Society of Hos- 1085; Mesalamine in Ulcerative Colitis, 140; Ondansetron: A tion (CC) 280; dosage form, conversion (PEC) 80; utilization, pital Pharmacists (NC) 1431 CSehreomtootnhine raRpeyce-pItnodru c(e5d- HTN3a)u seAan taagnodn iVsotm iftoirn gA,n ti3n6e7o;p lPaesgtaidce - Hucmosatn (Li)m 6m8u1n odeficiency virus, cost vs. disease progression, Ket4a75m ine, with succinylcholine, intubation, children (DIAS) mmuasneo deBfoivciinee:n cyR epDlisaecaesmee,n t1 0T92h;e raPrpayv asftoar tiSne veSroed iCuomm, bian Needw Im- 1431p;a tid extra(n,P ECi)nh i4b1i4t;i on« (DIAS) ig6, 06t;e stdirnugg suetrivliiczeast io(nN C()P EP) Ket1o3c2o1;n azpoitlyer,i asaisd vevresresi ceoflfoerc ts( A)( A)3 953;9 7;u tihleipzaattoiotno xi(cPiEtPy) (1C3R7)4 HMG-CoA Reductase Inhibitor, 388; Quinapril: A New Sec- 1374; isoniazid, peripheral neuropathy (L) 100; mortality Ketorolac, utilization, formulary restriction (L) 1399 ond-Generation ACE Inhibitor, 499; Selegiline: Initial or Ad- (NC) 338; transmission prevention (NC) 1157 Kidney failure, AIDS, pentamidine (RPR) 1171; calcium car- jNuenwct iSvpee cTihfeicr apSye rootfo nPianr kiRnesuopnt’ask eD iBsleoacske,e r,3 6;9 52S;er tSriamlivnaes:t atAi n: Hydhreaarlta zfianileu,r e,c ormepviaerwe d (Aw)i th1 35f1e lodipine (FF) 1199; congestive tbioonna t(eL ) (D1I26A9S,) p9h4a5r;m adciogkoixnient iicmsm u(nCeR ) Fa1b3,1 5;d iggolxoimne rduilsasro cifai-lt ra- CAa pRseaviiceiwn ionf DIetsr mPahtaorlmoagciocl oagnyd aPnedr ipChleirnailc alP aUisne ,D i2s5o7r;d erTso,p ic3a8l1 HHyyddrroocchhlloorroitch iaacziid,d ea,d mcixotmupraer,e dp arweintthe rfaell onduitpriintei on( FF()C C)1 19288 0 tpihoons prhataet,e inbdienxd er(sC C)( DI1A6S9); h9e4p2a;t icr ifdarmupgi nc l(eSarRa)n c7e4 3( A) 1214; Foswciathr neatcy csloovdiiru m(,F Fa)d v4e3r;s ep hareramcatcioonksi,n erteivcise w (F(FF)F )4 24;4 ;p hcaormmpaacroeld- Hydwritohc obrettiasmoenteh,a soasnteh,m ad,e xraemveitehw as(oPnAe), 73a,s t(hPmAa) (9P9A8;) c7o3 mpared KnaMpapry,l aDnadv i(dN CA). , 9d0e6a n, School of Pharmacy, University of ogy (FF) 42; review (FF) 41 Hydroxychloroquine, pharmacokinetics, rheumatoid arthritis France, medication errors (PEP) 1113 (RPR) 1302 Francke, Donald E., biographical sketch (SC) 425 3-Hydroxyquinidine, toxicity (L) 867 Hypercholesterolemia, simvastatin (FF) 257 Hyperkalemia, AIDS, pentamidine (RPR) 1171 Hyperphosphatemia, calcium carbonate (DIAS) 945; phos- G phate binders (DIAS) 942 Labeling, fentanyl (L) 1011 Hypersensitivity, see Allergy Labetalol, beta-adrenergic receptor response, racial groups (A) Hypertension, crisis, ephedrine (CR) 1068, oxymetazoline (CR) 827; hydrochloride, stability (SR) 465 1068, phenylephrine (CR) 1068; economic analy ses (PEC) Labor, prostaglandin E,, gel compared with suppository (RPR) Gabapentin, pharmacokinetics (A) 979; review (A) 982 289; enalaprilat,i (SR) 25; felodipine, review (FF) 456 Gamma hydroxy butyrate, illicit use, toxicity (NC) 114 1196; finger oscillometric blood pressure device (RPR) 1310; Laboratories, interlaboratory effects, warfarin, international Gastric obstruction, extended-release tablets (L) 678 mesna (L) 867; nifedipine (L) 99 normalized ratio (TC) 1190 DICP, The Annals of Pharmacotherapy = 199] December, Volume25 ® 1435 Lactate, biochemical marker, nutrition support (A) 265 1400, Plicamycin Infusion, 215, Potassium Supplements vs. Lake, Kathleen D., Albert B. Prescott/Glaxo Leadership Potassium-Sparing Diuretics, 439, Ranitidine Does Not In- Award, Phi Delta Chi (NC) 450 hibit Theophylline Metabolism, 1139, Subtherapeutic Drug Lamotrigine, pharmacokinetics (A) 979; review (A) 983 Concentrations and Compliance, 1016 Laemaps,es K(eNnCn)e th1,03 8M erck Foundation Fellow in Infectious Dis- CoArnrgeicotpiloansst,y , Cl1o2n7i4d,i nFei guPraetsc h TTroaxniscpiotsye,d ,6 821,0 1D7,i pyMreicdhaanmioclael in NNaafdaorleolli,n ,p hfairgmuarce okcriendeitt ic(sL) (3D21S P) 965 Lamy, Peter P., endowed chair in Geriatric Pharmacotherapy Ventilation, 1017, References Misnumbered, 876 Naf(cAi)ll i1n5,5 interaction, warfarin (CR) 598; postantibiotic effect Law(sNC,) Co2n2t6r olled Substances Act, cancer patients (A) 1229; liti- LLeeuuckoevmoirai,n , imlmocuanl et isgsluoeb urleianc,t iroenv i(eSwR )( D2S4P9) 811; lithium (TC) Nahata, Milap C., 1991 Distinguished Teaching Award, Ohio gation, review (SC) 195; patient counseling (L) 1274; psy- 948 NalSitdaitxei cU naicviedr,s itiynt e(raNcCt)i on5,7 2c ations (DIR) 1250 chotherapeutic agents, refusal (A) 849 Lidocaine, absorption, age (SR) 463; clearance, kidney failure Nal pediatric ¢ 4 y resuscitation (TC) 768 Lead, toxicity (CR) 932 (A) 1218; pediatric cardiopulmonary resuscitation (TC) 768 Naproxen, aseptic meningitis (SR) 1183 Letters, Accidental Intravenous Infusion of Sodium Hypochlo- Lisinopril, hyponatremia (L) 873; interaction, lithium (L) 101 National Association of Chain Drug Stores, see Association rite, 1008; Accumulation of 3-Hydroxyquinidine Following Literature, manual vs. computer-based searches (L) 214, (L) News (NC) Chronic Quinidine Therapy, 867; Acute Pancreatitis Associat- 875 Necrosis, renal papillary, flurbiprofen (L) 870 eMda tweirtnha lR oLxoirtahzreopmaymc ino n TNheeornaaptye,s , 1113173;7 ;A dAvdevresres eE fRfeecatcst ioofn s Litlheiuukme,m iac oc(aTiCn)e 9a4b8u se (A) 821; interaction, lisinopril (L) 101; NNeetoisltmiigcmini,n e pobsrtoanmtiidbei,ot imc yaesfftehcetn i(aA ) gr1a5v6i s (A) 1103 to Phenothiazine Antiemetics in AIDS, 1007; Aminoglyco- Lopez, Larry M., Fellow, ACCP (NC) 1038 Neuralgia, postherpetic, topical aspirin (DIAS) 1077 sides: Di ination of New Therapeutic Ranges, 558; Asep- Lorazepam, maternal, neonatal feeding difficulties, muscle tone Neuroleptic agents, see Psychotherapeutic agents ticM efniitn gitisI ndAuscseodc iaRtheadb dwoimtyh olMyusriosm,o n8a69b;- CCeDf3t,r ia1x3o9n5e; Drug Lydmipshorodmerass ,( L)h o1m1e3 7 care (A) 847 Neunrootlhieapztiince maanltiiegmneatnitc s s(yLn)d r1o0m0e7 , molindone (SR) 1071; phe- Utilization Evaluation in a Large Community Hospital, 872; Neurotoxicity, dine, renal (CR) 1175 Ciprofloxacin—Warfarin Interaction, 1397; Colchicine to Pre- Neutropenia, granulocyte-macrophage colony-stimulating fac- vent Halothane Hepatitis?, 21 1; Computer Monitoring tor (DIAS) 32 Ciprofloxacin-Theophylline Interactions, 1011; Confusing New Publications, see Book Reviews, Books Received Bacterial Endocarditis Recommendations, 1396; Cost Consid- News and Comments, i 14, 226, 338, 450, 572, 701, 905, 1037, eCroamtbiionnsa toifo nC onRveegrismieonns ftroo mC efAtmriinaoxgolney,c os3i19d;e -DCiogntoaxiinni—n g Magnesium sulfate, compatibility, amphotericin B (RPR) 123 a1n1d57 ,R e1s2e9a3r, ch1 43N0e;w ss,ee FalDsAo, NAesswosc,i aGteinoen raNle wsN,e wsE,d uOcbaittiuoanr y, Farewell, Old Friend or Un-Squill We Meet Again!, 320; Mania, clonazepam (SR) 938; fluoxetine (L) 1395 USPHS-CDC News, USPHS News, VIP News pDursu gE rCyotmhepmaantyo suIsn,f lu2e1n2c;e ,D u1r1a3g8e;s iDcr uPga-cIknadguec edLa bSeylisntge,m ic1 01L1u;- MMaaprrkoettiilnign,e , enccoacianiindee arbeumsoev a(lA ) (8N1C9) 1294; ethics (L) 1138; tria- Niatcoixni,c itsyu s(tLa)i ne1d0-1r4e lease, adverse reactions (DIAS) 253, hepa- 1Ea3r9l%y; AEnftfeiccto aogufl aatL iiognh t TBhreeraakpfya sti n oDn eethpe VBeiionav aTihlraobimlbiotsyi so,f Maszsoalcahmu sreetmtosv,a l wo(Em)e n1,2 63e strogen use (PEP) 418 Niacinamide, bullous pemphigoid (DIAS) 1187 tion of Acdy-cRleolveiars e anNdi feCdyicpl ospor3i1n7e; oEnf feKcit dnoefy C oFaudnmcitniiosnt raan-d Matmheenmoaxtiimces,, cpihpraorfmlaocxoakciinne,t itcosb,r abmaycctienri al( RPsuRs)c ep1t0i5b0il ity, cef- NNiicfoetdiinpei,n e,g umcl,e aurtainlciez,a tikoind n(eRyP Rf)a il7u3re0 (A) 1218; compared with Cyclosporine Concentrations in Renal Transplant Patients, McGhan, William F., executive director, Institute for Pharma- fbieolaovdaiiplianbei l(iFtyF ) (L1)1 993;1 7 hypertension (L) 99; sustained-release, 3E1n6a;l apEfrfielc-tI nodfu cPelda smAacpuhteer ePssiysc hoosni sC,y c5l5o8s;p oErriynet,h ro2m11y;c in— Felo- coepumteicnatl pErcoognroammisc s( N(CN)C )4 5900 6; USPC drug information devel- Nimodipine, bradycardia (CR) 247; clearance, kidney failure dipine Interaction, 1007; Erythromycin-Induced Agranulocy- Measles, vaccination levels (NC) 338 (A) 1216 tosis, 1136; Eternal Significance, 215; Evaluation of Con- MEDLINE, compared with EMBASE, TOXLINE, BIOSIS, NNiistorlednidpiipnien,e , clcelaeraarnacnec,e ,k ikdindenye yf afialiulruer e( A()A )1 211281 8 cEovmailtuaantti onD roufg GeUnsee riDcu-riBnrga ndA ntNiademper esKsnaonwtl eTdhgeer,a py1,1 382;1 3;F amo- IveDrIsSe, dCrourge rMeaEcDtLioInNs E(,R PRP)A SC10A6L2, PHARMLINE, IPA, ad- Nitrogen, urinary, biochemical marker, nutrition support (A) tidine and Cardiac Arrhythmia, 315; Fluoxetine and Glauco- Mefloquine, dosing regimen changed (NC) 450 265 ma, 436; Fluoxetine-Induced Mania in a Suicidal Depressed gitis, aseptic, b-CD3 (DIAS) 138, (L) 1395, Nomenclature, generic--brand name knowledge, physicians, Patient, 1395; Gastric Obstruction with Extended-Release naproxen (SR) 1183; bacterial, corticosteroids, infants, chil- pharmacists (L) 1138 TDaobslee tsO,r al6 78T;e gaHfeupra,t oc1e0l0l9u;l aHry pCearsrecnisniotmiavi tRye stpoo Cnlsien dtaom yLcoiwn-, Mepdererni d(iPnEeD,) co5n42c;e ntnreaotniaotness,, cpeofsttroipaexroantei ve( SR()R P2R7) 724; taste al- Nor(tDrSiPp)t yl1i2n0e9,; actlteeanrtainocne ,d ekfiicdinte yd isfoarilduerre w(iAt)h 1h2y1p7e;r apcthiavrimtayc oki- 317; Imipenem/Cilastatin Drug Utilization Evaluation in a teration (L) 1137 netics (TM) 1368 Nutrition, parenteral, drug vehicle, review (CC) 276, fluid bal- Large Community Hospital, 1399; Inadvertent Administration Mercaptopurine, myasthenia gravis (A) 1105 oIfn tArcaevetnoohuesx amAdimdien i Instead ofo Afc etaMzetohlylapmreiddnies,ol one1 00; IAnacdevtearttee nitn Mescoasltaemrioinde ,e naedmvaesr se( FFr)e ac1t4i2o;n sc o(mFpFa) re1d43 ; wictohm psaurlefads alwaiztihn ec or(tFiF-) a(nAc)e ,2 6I5C U patients (RPR) 119; support, biochemical markers a Child, 436; Interaction of Phenothiazine and Related Drugs 142; pharmacokinetics (FF) 141; review (FF) 140; ulcerative and Caffeinated Beverages, 437; Ketorolac Formulary Re- colitis (L) 1015 striction and Usage Evaluation, 1399; Lisinopril-Induced Mesna, hypertension (L) 867 O-P Lithium Toxicity, 101; Manual or Computer-Based Literature Metabolism, theophylline, ranitidine inhibition (L) 1139 Searches: Is One Best for Pharmacovigilance?, 214; Meperi- Methicillin, postantibiotic effect (A) 155 dine-Induced Taste Alteration, 1137; Mesna Therapy and Hy- Methixene, compared with selegiline, Parkinson’s disease (FF) pertension, 867; Methyldopa-Induced Granulomatous Hepati- 39 Obituary (NC), Green, Melvin W., 1294 tis, 1269; Neonatal Fever and Cyanotic Spells from Maternal Methotrexate, asthma, review (PA) 999; myasthenia gravis (A) Obstetrics, gentamicin pharmacokinetics, postpartum endomy- Chlorpromazine, 1009; Nitrate Tolerance: Does TID Isosor- 1105 ometritis (RPR) 1306 bide Dinitrate Mean Dosing Every Eight Hours?, 1272; Pen- Mothvuld 1 hepatitis (L) 1269 Obstruction, pseudo-, procainamide (SR) 1334 toxifylline-Induced G inal Bleeding, 315; Peripheral 3-Methylhistidine, biochemical marker, nutrition support (A) 265 Ofloxacin, interaction, cations (DIR) 1250; pregnancy (SR) Neuropathy in HIV Patient After Isoniazid, 100; Pharmacist Methylphenidate, attention deficit disorder with hyperactivity 1181 Involvement in Society of Critical Care Medicine, 1398; (DSP) 1208; hydrochloride, cocaine abuse (A) 820 Ondansetron, adverse effects (FF) 377, compared with meto- Phenytoin-Tizanidine Interaction, 1273; Possible Dissociation Methylprednisolone, acetate, intravenous administration (L) clop ide (FF) 373; compatibili I (L) 869; of the Digibind—Digoxin Complex in Renal Failure, 1269; 436; asthma (PA) 73; myasthenia gravis (A) 1105 pharmacodynamics (FF) 369; pharmacokinetics (FF) 369; Possible Procainamide-Induced Myopathy, 436; Preliminary Metoclopramide, clearance, kidney failure (A) 1215; compared pharmacology (FF) 367; review (FF) 367 Clinical Evidence for Analgesic Effect of Vapreotide, 1136; with ondansetron (FF) 373; urinary retention (SR) 469 Ophthalmopathy, Graves’, cyclosporine (DIAS) 750 Probable Famotidine-Induced Thrombocytopenia, 678; Pseu- Metoprolol, clearance, kidney failure (A) 1218; compared with Opinions, see An Opinion; Editorials domonas aeruginosa Resistance to Ceftazidime, 871; Rela- felodipine (FF) 1198; pharmacokinetics (DSP) 965; pharma- Osteomyelitis, home care (A) 844 tionship Between Tranylcypromine Sulfate Dose and cology (DSP) 962 Oxazepam, clearance, kidney failure (A) 1220 M ine Oxidase Inhibition, 99; Renal Papillary Necrosis Mexiletine, interaction, theophylline (RPR) 727; pulmonary fi- Oxygen, biochemical marker, nutrition support (A) 265 Induced by Flurbiprofen, 870; Schizophyllan Augments De- brosis (SR) 1329 Oxymetazoline, hypertensive crisis (CR) 1068 of I lobulin-Secreting Cells upon Costimu- Midazolam, administration routes (DIAS) 476 Package inserts, Belgium (IR) 1002; NSAIDs, Saudi Arabia lation with Staphylocoocc cus aureus Cowan I, 101; Sources of Migraine, prophylaxis, calcitonin (DIAS) 1185, verapamil compared with US (IR) 863 Influence on the Prescribing Practices of Residents in Family (DIAS) 1076 Pain, cancer, management (A) 122. 5; patient-controlled analge- Medicine, 102; Streptokinase Versus Recombinant Tissue- Milrinone, congestive heart failure, review (A) 1352 sia (RPR) 1058 Type Plasminogen Activator, 1271; Subtherapeutic Serum Misoprostol, delirium (SR) 133 Pancreatic enzymes, prescription only, cystic fibrosis (NC) Drug Concentrations and Compliance, 103; Switching Mitomycin, superficial bladder cancer (A) 1357 1157 Haloperidol from Oral to IM Depot Formulation, 1270; ynd (SR) 1071 Pancreatitis, roxithromycin (L) 1137 Tetanus Toxoid Anaphylaxis, 870; Unresponsiveness to Monoamine oxidase inhibition, tranylcypromine sulfate, dose Pancuronium, pharmacodynamics (A) 58; pharmacokinetics Nifedipine Treatment, 99; Variable Theophylline Clearance in (L) 99 (A) 58 Cystic Fibrosis, 212; Vertigo Caused by Intravenous Imipen- Monoamine oxidase inhibitors, cocaine abuse (A) 820 Parkinson’s disease, selegiline, review (FF) 36; tricyclic antide- em/Cilastatin, 1009; Visual « ibility of Ond and tams, with beta-lactams, synergy (A) 974 pressants (DIAS) 137 Dexamethasone, 869; Vitamin K, and Anaphylactic Shock, Mood disorder, lithium, leukemia (TC) 948 PASCAL, compared with EMBASE, TOXLINE, MEDLINE, 871; Volmax: Simulated Gastrointestinal pH and Agitation Moricizine, use in study halted (NC) 1294 BIOSIS, IDIS, Core MEDLINE, PHARMLINE, IPA, adverse Studies, 438; We Use Drugs Too—More Pediatric Informa- Morphine, epidural, pruritus, cimetidine (RPR) 716; utilization drug reactions (RPR) 1062 tion in Review Articles, 559 (PEP) 1374 Patient-controlled analgesia, evaluation (RPR) 1058 Comments/Author Replies, Adverse-Effect Profile of Sus- Moxalactam, postantibiotic effect (A) 156 Patient education, asthma (E) 668; clinical pharmacy (A) 164; tained-Release Niacin, 1014, Aminoglycoside Dosing, 1141, Mupirocin, methicillin-resistant Staphyolococcus aureus laws (L) 1274; metered-dose inhalers (PA) 641 Attribution of Blame in Drug-Induced Thrombocytopenia, vaginitis (SR) 1331 Patient information, litigation, review (SC) 195 874, Consideration of AmphotericBin Hep icity, 559, Muromonab-CD3, aseptic meningitis (DIAS) 138, (L) 1395 Patients, outpatients, monitoring infections (A) 840 Fluoxetine Adverse Effects and Drug Interactions, 1273, Le- Myasthenia gravis, choli hibitors (A) 1103; cortico- Pediatrics, activated charcoal, pharmacokinetics, phenytoin poi- gal Duty to Counsel, 1274, Lisinopril-Induced Hyponatre- steroids (A) 1104; cyclosporine (A) 1106; immunoglobulin soning (PED) 646; alprostadil, congenital heart disease, mia, 873, Manual Versus Computer-Based Literature (A) 1106; immunosuppressive agents (A) 1105; neostigmine neonatal transport (PED) 408; carbamazepine, therapeutic Searches for Adverse Drug Reactions, 875, Mesalamine in bromide (A) 1103; review (A) 1101 monitoring (PED) 1109; cardiopulmonary resuscitation, in- Ulcerative Colitis, 1015, Metered-Dose Inhalers, 321, Ori- Myocardial infarction, acute, heparin (TC) 613; thrombolytics, fants, children (TC) 760; ceftizoxime, neonates, infants (RPR) gins of Clinical Pharmacy, 1142, Parenteral H,-Receptor administration delay (A) 1v96 344; cefuroxime axetil, suspension (PED) 1236; clonidine, Antagonist Intervention, 681, Pharm.D.: All or Some?, 679, Myopathy, procainamide (L) 436 growth acceleration (DIAS) 1339; corticosteroids, meningitis 1436 = DICP,The Annals of Pharmacotherapy ® 199] December, Volume 25 Index (PED) 542; diphenhydramine toxicity, varicella zoster (CR) tidepressants (TM) 1368; vecuronium (A) 59; vigabatrin (A) Professional competence, determinants (O) 205; patient out- 130; indomethacin, intraventricular hemorrhage, neonates 979 comes (O) 208 (TC) 1344, (E) 1385; information, review articles (L) 559; ke- Pharmacology, altretamine (FF) 147; capsaicin (FF) 382; clo- Propafenone, clearance, kidney failure (A) 1220 tamine/succinylcholine, intubation (DIAS) 475; lorazepam, fazimine (FF) 525; felodipine (FF) 1193; foscarnet sodium Prophylaxis, antibiotic, coronary bypass surgery (TC) 478; en- maternal, feeding difficulties, muscle tone disorders (L) 1137; (FF) 42; goserelin acetate (FF) 796; idarubicin (FF) 506; neu- docarditis, erythromycin (L) 1396; migraine, calcitonin medication errors, France (PEP) 1113; neonates, ceftriaxone, romuscular blocking agents (A) 54; pravastatin (FF) 388; (DIAS) 1185, verapamil (DIAS) 1076; neonatal intraventricu- Citrobacter freundii meningitis (SR) 27, ventilator parameters quinapril (FF) 499; sertraline (FF) 952; sympatholytic agents lar hemorrhage, indomethacin (TC) 1344, (E) 1385; surgical, (PED) 272; phenytoin, teratogenicity (PED) 987; pro- (DSP) 962 cefotetan compared with cefoxitin (RPR) 10 cainamide, neonates (PED) 68; theophylline, dosage (PED) Pharmacotherapy, see also, Pharmacy, clinical; changes in Propoxyphene, clearance, kidney failure (A) 1217 179; thrombosis, heparin (PED) 853 practice (O) 431; patient outcomes (O) 208; prescribing er- Propranolol, beta-adrenergic receptor response, racial groups Pediatrics (PED), Carbamazepine Dosing for Pediatric Seizure rors, prevention (O) 1388; professional interaction, physicians (A) 825; clearance, kidney failure (A) 1215; compared with Disorders: The Highs and Lows, 1109; Differences in Pheny- (O) 1132; research (E) 1129; Society of Critical Care chi ide, alcohol withd: | (DIAS) 32; compared toin Biotransformation and Susceptibility to Congenital Mal- Medicine, pharmacist involvement (L) 1398 with felodipine (FF) 1199; pharmacokinetics (DSP) 965; phar- formations: A Review, 987; Evaluation of Three Theophylline Pharmacotherapy Case Reports, Agranulocytosis Associated macology (DSP) 963 Dosing ane in Pediatric rem, 179; es Leger with Enalapril, 461; Amantadine Neurotoxicity in a Pediatric Prostaglandin E,, see Alprostadil Patient with Renal Insufficiency, 1175; Aztreonam-Induced Prostaglandin E,, gel compared with suppository, cervical macokinetic Simulation of the Effect of Multiple-Dose Acti- Myelosuppression During Treatment of Pseudomonas aerugi- ripening (RPR) 456 vated Charcoal in Phenytoin Poisoning—Report of Two nosa Pneumonia, 594; Clinical and Pharmacokinetic Profiles Protein, acute phase, biochemical marker, nutrition support (A) Pediatric Cases, 646; Prostaglandin E, Treatment of Congeni- of Digoxin Immune Fab in Four Patients with Reel Impair- 265; visceral, biochemical marker, nutrition support (A) 265 tal Heart Disease: Use Prior to Neonatal Transport, 408; The ment, 1315; Decreased Hypoproth i to PP p. d, aeruginosa, resistance, ceftazidime (L) 871 Impact of Changing Ventilator Parameters on Availability of Warfarin Secondary to the Warfarin—Nafcillin Interaction, Psoriasis, vitamin D (DIAS) 753, review (A) 835 Nebulized Drugs in an In Vitro Neonatal Lung System, 272; 598; Diphenhydramine Toxicity in Three Children with Vari- Psychosis, enalapril (L) 558 The Role of Corticosteroids in Infants and Children with Bac- cella-Zoster Infection, 130; Gentamicin and Vancomycin Re- Psychotherapeutic agents, anticepressants, concomitant drug terial Meningitis, 542; The Safety, Efficacy, and Tolerability moval by Continuous Venovenous Hemofiltration, 127; Hy- use (L) 213; leptics, drug ion, Italian mental of Cefuroxime Axetil Suspension in Infants and Children Re- pertensive Crisis from Chronic Intoxication with Nasal health services (PEP) 296; prescriptions, ambulatory care ceiving Previous Intravenous Antibiotic Therapy, 1236; Ther- Decongestant and Cough Medications, 1068; Hypotension (PEP) 85; refusal, laws (A) 849; iricyclic antidepressants, apeutic Monitoring and Pharmacokinetic Evaluation of Pro- and Bradycardia Possibly Associated with Intraocular Injec- Parkinson's disease (DIAS) 137 cainamide in Neonates, 68 tion of Acetylcholine, 1178; Impaired Water Homeostasis Pulmonary and Allergy, Corticosteroids for Acute, Severe Pegademase bovine, adverse reactions (FF) 1094; interaction, Following Mixed Carb pine and Ph harhi 1 Over- Asthma, 72; Optimizing Drug Delivery from Metered-Dose pentostatin, vidarabine, review (FF) 1094; pharmacokinetics dose, 354; Intravenous Esmolol in Acute Aortic Dissection, Inhalers, 638; Pathogenesis of Asthma: Therapeutic Implica- (FF) 1094; review (FF) 1092 735; Ketoconazole Hepatotoxicity in a Patient Treated for En- tions, 993 Pemphigoid, bullous, niacinamide (DIAS) 1187 vironmental Illness and Systemic Candidiasis, 1321; Ni- Pulmonary fibrosis, mexiletine (SR) 1329 Penbutolol, pharmacokinetics (DSP) 965; pharmacology (DSP) modipine and Bradycardia in Acute Stroke—Drug or Dis- Pyridostigmine bromide, myasthenia gravis (A) | 103 963 ease?, 247; Oral Vancomycin-Induced Rash: Case Report and Pyruvate, biochemical marker, nutrition support (A) 266 Penicillin G, postantibiotic effect (A) 155 Review of the Literature, 1326; Phenothiazine-Associated Ap- Penicillins, drug information, outpatients (RPR) 925; postantibi- nea in Two Siblings, 244; Phenytoin Hypersensitivity Syn- otic effect (A) 154 drome: A Case Report, 929; Ranitidine-Theophylline Interac- Pentamidine, nephrotoxicity, hyperkalemia, AIDS (RPR) 1171; tion—Fact or Fiction?, 21; Seizure Activity Associated with Q-R utilization (PEP) 1374 Imipenem Use: Clinical Case Reports and Review of the Lit- Pentostatin, interaction, pegademase bovine, review (FF) 1094 erature, 351; Suspected Central Nervous System Toxicity Pentoxifylline, gastrointestinal bleeding (L) 315 from Inadvertent N idal Antiinfl y Drug Over- Peritonitis, chemical, vancomycin (SR) 602 dose, 1066; Ten Cases of Acute Lead Intoxication Among Quinapril, adverse reactions (FF) 502; compared with captopril Personnel Placement, see separate section: ADVERTISERS Bridge Workers in Louisiana, 932 (FF) 500; compared with enalapril (FF) 501; interactions (FF) Pharmacodynamics, atracurium (A) 59; curare (A) 57; dipyri- Pharmacy, clinical, see also, Pharmacotherapy; dosage form 502; pharmacokinetics (FF) 500; pharmacology (FF) 499; re- damole (FF) 1086; goserelin acetate (FF) 797; ondansetron conversion (PEC) 80; education, B.S. vs. Pharm.D. (SC) 94, view (FF) 499 (FF) 369; pancuronium (A) 58; pravastatin (FF) 389; suc- (L) 679, (L) 1400; clinical, medical vs pharmaceutical (SR) Quinidine, gluconate, Plasmodium falciparum (NC) 906; 3-hy- cinylcholine (A) 57; vecuronium (A) 58 1336; education/ practice, Zimbabwe (IR) 302; ICU patients, droxyquinidine toxicity (L) 867; with digoxin/warfarin, inter- Pharmacoeconomics, analyses, hypertension (PEC) 289; con- fluid balance (RPR) 119; origins (L) 1142; patient informa- action, sucralfate (SR) 745 version, aminoglycoside regimens to ceftriaxone (L) 319; tion, litigation (SC) 195; patient intervention (A) 164; quality Quinine, parenteral, discontinuation (NC) 906 cost, antibiotic dosing frequencies (PEC) 546, conversion (RC) 1133; University of California, San Francisco (SC) 308 Quinolones, interaction, cations (DIR) 1249, theophylline, from parenteral to oral H,-receptor antagonists (PEC) 80, HIV PHARMLINE, compared with EMBASE, TOXLINE, MED- meta-analysis (DIR) 191; postantibiotic effect (A) 154 patient drugs (PEC) 414; drug usage evaluation, imipenem/ LINE, BIOSIS, IDIS, Core MEDLINE, PASCAL, IPA, ad- Race, beta-adrenergic receptor response, differences (A) 824 cilastatin (RPR) 348; intensive care units, charge, reimburse- verse drug reactions (RPR) 1062 Ranitidine, conversion of iv to po (SR) 251; interaction, theo- ment (CC) 1231; ranitidine, conversion of iv to po (SR) 251 Phenobarbital, with carbamazepine, acute water intoxication phylline (CR) 21; theophylline metabolism inhibition (L) Pharmacoeconomics (PEC), Economic Analyses in Hyperten- (CR) 354 1139 sion: Applications for Healthcare Providers, 289; Evaluating Phenothiazine, apnea (CR) 244; interaction, caffeine (L) 437 Rash, vancomycin (CR) 1326 the Cost Impact of Intravenous Antibiotic Dosing Frequen- Phenylephrine, hypertensive crisis (CR) 1068 Release, Volmax (L) 438 cies, 546; Evaluation of Direct Pharmacist Intervention on Phenylpropanolamine, no interaction, indomethacin (RPR) 234 Research, academic pharmacy practice (E) 1129; funding, pro- Conversion from Parenteral to Oral Histamine H,-Receptor Phenytoin, concentrations, compliance (L) 103; hypersensitivity ductivity (E) 669 Antagonist Therapy, 80; The Relationship Between Outpa- (CR) 929; interaction, tizanidine (L) 1273; toxicity, activated Research/Practice Reports, A Comparative Evaluation of the tient Drug Costs and Disease Progression in the Human Im- charcoal, pharmacokinetics (PED) 646 Safety and Efficacy of Cefotetan and Cefoxitin in Surgical munodeficiency Virus-Infected Population, 414 Phosphate binders, kidney failure (DIAS) 942 Prophylaxis, 10; Assessing the Effects of Antihypertensive Pharmacoepidemiology (PEP), Characteristics of Medication Physicians, intervention, albumin utilization (RPR) 239; phar- Medication on Cerebral Blood Flow: Demonstration in Inter- Errors in Pediatrics, 1113; Clinical and Economic Impact of macist interaction (O) 1132; prescribing errors, prevention (O) nal Carotid Artery Occlusion, 1299; Ceftizoxime Disposition Oral Ciprofloxacin as Follow-Up to Parenteral Antibiotics, 1388; prescribing practices, drug information sources (L) 102; in Neonates and Infants During the First Six Months of Life, 857; Medication Usage Patterns in Patients with Human Im- residencies, prescription writing (RPR) 17 344; Ciprofloxacin in Patients with Mycobacterial Infections: munodeficiency Virus Infection: A Comparison of Patient Re- Pindolol, beta-adrenergic receptor response, racial groups (A) Experience in 15 Patients, 919; Clinical Evaluation ofa Finger ported Medication Usage with Medical Chart Review, 1374; 826; pharmacokinetics (DSP) 965; pharmacology (DSP) 963 Oscillometric Blood Pressure Device, 1310; Combined Use of Pattern of Neuroleptic Drug Use in Italian Mental Health Ser- Piperacillin, interaction, tobramycin (SR) 357; postantibiotic ef- Ciprofloxacin and Sucralfate, 578; Comparative Attitudes to vices, 296; Psychotropic Medication Prescription in US Am- fect (A) 155 Verbal and Written Medication Information Among Hospital — Medical Care, 85; Tryptophan Toxicity: A Pharma- Pityriasis versicolor, ketoconazole (A) 395 Outpatients, 925; Comparative Efficacy of Intravaginal logic Review of Eosi hili Myalgia Syndrome, Placebo, hypervagotonia (SR) 471 Prostaglandin E, in the Gel and Suppository Forms for Cervi- 1259; Use of Estrogens Among Middle- Aged Massachusetts Plasmapheresis, cyclosporine, pharmacokinetics (L) 211 cal Ripening, 456; Comparative Study of Fluconazole and Women, 418 Platelets, adverse drug reactions (L) 874 Clotrimazole in the Treatment of Vulvovaginal C anndidiasis, Pharmacokinetics, acetylcysteine absorption, activated charcoal Pleural effusion, malignant, talc (DIAS) 1187 582; Comparison and Evaluation of Nine Rin eg (TC) 1081; actisomide (RPR) 231; activated charcoal, pheny- Plicamycin, dosage schedule (L) 215 Databases Concerning Adverse Drug Reactions, 1062; Com- toin poisoning (PED) 646; altretamine (FF) 147; aminoglyco- Pneumocystis carinii, p i tr imethopr i parison of Steady-State Serum Concentrations of Digoxin in sides, two- vs. three-point method (TM) 635; amitriptyline zole (DIAS) 941 Tablets (Lanoxin) and Capsules (Lanoxicaps) in the Elderly, (TM) 1368; atracurium (A) 59; capsaicin (FF) 383; cef- Pneumonia, Pneumocystis carinii, trimethop 1043; Evaluation of aN on-Food and Drug Administration- menoxime, bacterial susceptibility (RPR) 1050; ceftazidime, zole (DIAS) 941; Pseudomonas aeruginosa, aztreonam (CR) Approved Use of Cimetidine: Treatment of Pruritus Resulting elderly (G) 285; ceftizoxime, neonates, infants (RPR) 344; 594 from Epidural Morphine Analgesia, 716; Evaluation of an ciprofloxacin, bacterial susceptibility (RPR) 1050; clofaz- Ponte, Charles D., USPC panel of experts, family practice (NC) Imipenem/Cilastatin Target Drug Program, 348; Gentamicin imine (FF) 526; colony- stimulating | factors (DSP) 491; curare Pharmacokinetics in Postpartum Women with Endomyometri- (A) 58; cyclosporine,p (L) 211; desip Potassium, suppl VS. p ium-sparing diuretics (L) 439 tis, 1306; Improving Prescription-Writing Skills in a Family (TM) 1368; digoxin immune Fab, kidney failure (CR) 1315; Pravastatin, adverse reactions (FF) 392; interactions, review Practice Residency, 17; In Vitro Evaluation of Bleomycin-In- dipyridamole (FF) 1086; doxepin (TM) 1368; ES monoclonal (FF) 392; pharmacodynamics (FF) 389; pharmacokinetics duced Cell Lethality from Plastic and Glass Containers, 14; antibody (FF) 787; felbarnate (A) 979; felodipine (FF) 1195; (FF) 389; pharmacology (FF) 388; review (FF) 388 or | ular Teicoplanin Once Daily for Skin fludarabine (FF) 519; foscarnet sodium (FF) 42; gabapentin Prazosin, compared with felodipine (FF) 1199; vasodilatory and Soft-Tissue Infections, 914; Mathematical Examination of (A) 979; gentamicin, endomyometritis (RPR) 1306; goserelin stimulus, dynamic cerebral blood flow (RPR) 1299 Dual Individualization Principles (I): Relationships Between acetate (FF) 797; human monoclonal antibody (FF) 780; hy- Prednisone, asthma (PA) 73; myasthenia gravis (A) 1105 AUC Above MIC and Area Under the inhibitory Curve for droxychloroquine, rheumatoid arthritis (RPR) 1302; idaru- Pregnancy, ofloxacin (SR) 1181 Cefi Ciprofl in, and Tobramycin, 1050; Mecha- bicin (FF) 506; imipramine (TM) 1368; immune globulin Premenstrual syndrome, verapamil (DIAS) 361 nism of Interaction Between Theophylline and Mexiletine, (DSP) 807; interleukin-2 (DSP) 493; lamotrigine (A) 979; Prescribing, family medicine residents, drug information 727; Meperidine Serum Concentrations and Analgesic Re- mesalamine (FF) 141; nortriptyline (TM) 1368; ondansetron sources (L) 102; patterns, geriatrics (G) 186; skills, residents sponse in Postsurgical Patients, 724; Monitoring Serum (FF) 369; pancuronium (A) 58; pegademase bovine (FF) (RPR) 17 Digoxin Concentrations During Digoxin Immune Fab Thera- 1094; p in (FF) 389; procainamide, neonates (PED) 68; —— ambulatory care, Saudi Arabia (IR) 90; psy- py, 1047; Patient Acceptance of Nordiject: A New Drug De- quinapril (FF) 500; sertraline (FF) 953; simvastatin (FF) 258; ic agents, 'y care (PEP) 85 livery System for Growth Hormone, 585; Patterns of Nicotine succinylcholine (A) 57; sympatholytic agents (DSP) 964; to- Probucol, compared with simvastatin (FF) 260 Gum Use in a Health Maintenance Organization, 730; Pen- bramycin, bacterial susceptibility (RPR) 1050; tricyclic an- Procainamide, myopathy (L) 436; pseudo-obstruction (SR) 1334 tamidine-Associated Nephrotoxicity and Hyperkalemia in Pa- DICP, The Annals of Pharmacotherapy ® 1991 December, Volume 25 8 1437 tients with AIDS, 1171; Pharmacist Interventions Improve bramycin by Piperacillin, 357; Intravenous Enalaprilat Thera- Thallous chloride, stress imaging, dipyridamole (FF) L085 Fluid Balance in Fluid-Restricted Patients Requiring Parenter- py for Hypertension, 25; Lidocaine Absorption and Theophylline, asthma, review (PA) 998; clearance, cystic fibro- al Nutrition, 119; Pharmacokinetic and Tolerance Evaluation Metabolism After Oropharyngeal Application in Young and sis (L) 212, kidney failure (A) 1219: concentrations, compli- of Actisomide, a New Antiarrhythmic Agent, in Healthy Vol- Young-Elderly Adults, 463; Local Tissue Reaction to Intra- ance (L) 103; dosage, pediatrics (PED) 179; interaction, unteers, 231; Physical Compatibility and Chemical Stability venous Fluorouracil, 249; Long-Term, Low-Dose Aspirin is ciprofloxacin, computer monitoring (L) 1011, mexiletine of Amphotericin B in Combination with Magnesium Sulfate Safe in Glucose-6-Phosphate Dehydrogenase Deficiency, (RPR) 727, quinolones, meta-analysis (DIR) 191, ranitidine in 5% Dextrose Injection, 123; Retrospective Evaluation of 1074; Mania Associated with Clonazepam, 938; Medical Ver- (CR) 21; metabolism, ranitidine inhibition (L) 1139; nebu- Patient-Controlled Analgesia Use in a Large Teaching Institu- sus Pharmaceutical Continuing Education: Are Both Appro- lized, ventilator parameters, neonates (PED) 273 tion, 1058; Steady-State Pharmacokinetics of Hydroxychloro- priate for the Pharmacist?, 1336; Naproxen-Induced Recurrent Therapeutic Controversies, Activated Charcoal and Acetylcys- quine in Rheumatoid Arthritis Patients, 1302; The Effect of Aseptic Meningitis, 1183; Neuroleptic Malignant Syndrome teine Absorption: Issues in Interpreting Pharmacokinetic Data, Phenylpropanolamine on 24-Hour Blood Pressure in Nor- Possibly Caused by Molindone Hydrochloride, 1071; 1081; Antimicrobial Prophylaxis in Coronary Bypass Surgery: motensive Subjects Administered Indomethacin, 234; Toxici- Ofloxacin During the Second Trimester of Pregnancy, 1181; A Critical Appraisal, 478; Controversies in Cardiopulmonary ty of Colistin in Cystic Fibrosis Patients, 1168; Use of Albu- Possible Association of Pulmonary Fibrosis with Mexiletine, Resuscitation: Pediatric Considerations, 760; Indomethacin min in a University Hospital: The Value of Targeted 1329; Procainamide-Induced Pseudo-Obstruction in a Diabet- for Prevention of Neonatal Intraventricular Hemorrhage, Physician Intervention, 239; Vancomycin Protein Binding in ic Patient, 1334; Provocation Tests in a Chlorprome “anone- 1344; Leukemia in Bipolar Mood Disorder: Is Lithium Con- Patients with Infections Caused by Staphylococcus aureus, Induced Fixed Drug Eruption, 604; Stability of Ceftriaxone traindicated?, 948; The Controversy of Heparin Therapy as an 713 Sodium in Peritoneal Dialysis, 741; Stability of Labetalol Hy- Adjunct to Thrombolysis in Acute Myocardial Infarction, 613; Resistance, ceftazidime, Pseudomonas aeruginosa (L) 871 drochloride in Distilled Water, Simple Syrup, and Three Fruit The Dose of Epinephrine During Cardiopulmonary Resuscita- Resuscitation, cardiopulmonary, epinephrine, dosage (TC) 773, Juices, 465; Successful Treatment of Neonatal Citrobacter tion in Humans: What Should It Be?, 773; Warfarin and the infants, children (TC) 760 freundii Meningitis with Ceftriaxone, 27; Thrombocytopenia International Normalized Ratio: Reducing Interlaboratory Ef- Review Articles, Anticpileptic Medications in Development, Possibly Caused by Structurally Related Third-Generation fects, 1190 978; Are There Beta-Adrenergic Receptor Response Differ- Cephalosporins, 135; Urinary Retention—An Unusual Dys- Therapeutic monitoring, procainamide, neonates (PED) 68 ences Between Racial Groups?, 824; BCG and the Treatment tonic Reaction to Continuous Metoclopramide Infusion, 469; Therapeutic Monitoring (TM), Early Individualization of Tri- of Superficial Bladder Cancer, 1355, Changing Strategies in Urinary Retention Associated with Ipratropium Bromide, 939 cyclic Antidepressant Dosing Using a Bayesian Pharmacoki- the Management of Chronic Congestive Heart Failure, 1349; Simvastatin, adverse reactions (FF) 261; compared with netic Model, 1368; Three-Point Versus Two-Point Method for Clinical Pharmacology of the Neuromuscular Blocking cholestyramine (FF) 260; compared with gemfibrozil (FF) Early Individualization of Aminoglycoside Doses, 635 Agents, 54; Effect of Age on Lymphocyte Betay-Adrenergic 260; compared with probucol (FF) 260; pharmacokinetics Thiethylperazine, neuroleptic malignant syndrome (L) 1007 Responsiveness, 532; Intradermal Hepatitis B Vaccination, (FF) 258; review (FF) 257 Thiotepa, superficial bladder cancer (A) 1357 628; Is Heparin Really Necessary in the Lock, and, If So, How Smith, Gary H., USPC drug information development programs Thompson, Dennis F., USPC drug information devlopment pro- Much?, 399; Ketoconazole in the Treatment of Pityriasis Ver- (NC) 450 grams (NC) 450 sicolor: International Review of Clinical Trials, 395; Misper- Smith, William E., Ph.D, student, Auburn University (NC) 906 Thrombocytopenia, ceftazidime, ceftriaxone (SR) 135; famoti- ceptions and Inadequate Pain Management in Cancer Patients, Society of Critical Care Medicine, pharmacist involvement (L) dine (L) 678; mechanism (L) 874 1225; Monitoring Chronic Outpatient Infections: Providing 1398 Thrombocytopenic purpura, idiopathic, immune globulin, re- Comprehensive Home Healthcare Pharmacy Services, 840; ety of Infectious Diseases Pharmacists, see Association view (DSP) 808 Overview of Biochemical Markers Used for Nutrition Sup- News (NC) Thrombolytic agents, administration delay, myocardial infare- port, 265; Overview of Synergy with Reference to Double Sodium bicarbonate, pediatric cardiopulmonary resuscitation tion (A) 1096 Beta-Lactam Combinations, 972; Pharmacologic Treatment of (TC) 764 Thrombosis, acute myocardial infarction, heparin (TC) 613; Cocaine Abuse, 818; Purdue Stepped Approach Model: Ap- Software Reviews, reFORM Software, 106 deep vein, therapy institution (L) 1397; neonatal, heparin, plication to Pharmacy Practice, 164; Reducing Time Delays in Spain, antibiotics, utilization (IR) 662 thrombolytics (PED) 853 the Administration of Thrombolytic Therapy to Patients with Special Contributions, A Brief History of the “DIAS Rounds,” Ticarcillin, postantibiotic effect (A) 155 Acute Myocardial Infarction, 1096; Safe Use of Codeine in 307; A Sketch of Donald E. Francke: Founder and First Edi- Timolol, pharmacokinetics (DSP) 965 the Recovering Alcoholic or Addict, 49; The Effect of Renal tor, 425; Seventy Years in Retrospect, 1265; The Duty to Tizanidine, interaction, phenytoin (L) 1273 Failure on Hepatic Drug Clearance, 1214; The Postantibiotic Counsel: Reviewing a Decade of Litigation, 195; The Origins Tobramycin, interaction, piperacillin (SR) 357; pharmacokinet- Effect: A Review of In Vitro and In Vivo Data, 153; Thera- of the Clinical Pharmacy Program at the University of Cali‘ or- ics, bacterial susceptibility (RPR) 1050; postantibiotic effect peutic Advances in the Prevention of Hepatitis B: Yeast-De- nia, San Francisco, 308; The Pharm.D.: All or Some?, 94 (A) 156 rived Recombinant Hepatitis B Vaccines, 617; Therapeutic Stability, ceftriaxone sodium, peritoneal dialysis (SR) 741; la- Tocainide, clearance, kidney failure (A) 1218 Strategies for Myasthenia Gravis, 1101; Update on the Right betalol hydrochloride (SR) 465 Tocopherol, compared with selegiline, Parkinson's disease (FF) to Refuse Antipsychotic Medication, 849; Vitamin D Therapy Staphylococcus aureus, immunoglobulin synthesis, schizophyl- 38 in Psoriasis, 835 lan (L) 101; methicillin-resistant, vaginitis, mupirocin (SR) Tolerance, actisomide (RPR) 231; cancer patients (A) 1226; Rhabdomyolysis, bezafibrate (L) 869 1331; prophylaxis, coronary bypass surgery (TC) 478; van- isosorbide dinitrate (L) 1272 Rho Chi Lecture, Ideals and Innovation: Drugs, Generics, the comycin, protein binding (RPR) 713 Toxicity, colistin, cystic fibrosis (RPR) 1168; colony-stimulat- FDA, and the Pharmacist, 427; Progress and Problems: A Per- Staphylococcus epidermidis, prophylaxis, coronary bypass ing factors (DSP) 492; corticosteroids, asthma (PA) 77; sonal Perspective, 1133 surgery (TC) 478 diphenhydramine, varicella zoster (CR) 130; ephedrine, hy- Rifampin, acute hemolysis, renal failure (SR) 743; postantibiot- Steroids, cortico-, asthma, review (PA) 72; compared with im- pertensive crisis (CR) 1068; fludarabine (FF) 522; gamma hy- ic effect (A) 154 mune globulin, idiopathic thrombocytopenic purpura (DSP) droxy butyrate (NC) 114; 3-hydroxyquinidine (L) 867; idaru- Roxithromycin, pancreatitis (L) 1137 809; dosing, asthma (PA) 76; enemas, compared with bicin (FF) 512; interleukin-2 (DSP) 494; lead (CR) 932; Rybak, Michael J., Fellow, ACCP (NC) 1038; Probus Club mesalamine enemas (FF) 142; meningitis, infants, children nonsteroidal antiinflammatory drugs, overdose (CR) 1066; Award for Academic Achievement in Natural Sciences (NC) (PED) 542; myasthenia gravis (A) 1104; toxicity, asthma (PA) oxymetazoline, hypertensive crisis (CR) 1068; phenylephrine, 1038 77 hypertensive crisis (CR) 1068; phenytoin, pharmacokinetics, Streptokinase, administration delay, myocardial infarction (A) activated charcoal (PED) 646; tryptophan, epidemiology 1096; compared with alteplase (L) 1271; neonatal thrombosis (PEP) 1259; vitamin D (A) 837; water, carbamazepine/pheno- (PED) 853 barbital overdose (CR) 354 S Streptomycin, availability (NC) 1430 TOXLINE, compared with EMBASE, MEDLINE, BIOSIS, Succinylcholine, pharmacodynamics (A) 57; pharmacokinetics IDIS, Core MEDLINE, PASCAL PHARMLINE, IPA, ad (A) 57; with ketamine, intubation, children (DIAS) 475 verse drug reactions (RPR) 1062 Sucralfate, interaction, ciprofloxacin (RPR) 578, digoxin/quini- Transpl ion, renal, line, neurotoxicity (CR) 1175 Saudi Arabia, package inserts, compared with US inserts (IR) dine/warfarin (SR) 745, quinolones (DIR) 1254 Tranyleypromine sulfate, attention deficit disorder with hyper- 863; prescribing patterns, ambulatory care (IR) 90 Sulfamethoxazole, with trimethoprim, Pneumocystis carinii activity (DSP) 1209; MAO inhibition (L) 99 Schentag, Jerome J., Russell R. Miller Av ard, ACCP (NC) pneumonia (DIAS) 941 Trazodone, cocaine abuse (A) 819 1038 Sulfasalazine, oral, compared with mesalamine enemas (FF) Triazolam, market removal (E) 1263 Schizophyllan, immunoglobulin synthesis, Staphylococcus au- 142 Triglycerides, biochemical markers, nutrition support (A) 265 reus (L) 101 Sulfonamides, postantibiotic effect (A) 154 Trimethobenzamide, neuroleptic malignant syndrome (1) 1007 Seizures, imipenem/cilastatin (CR) 351 Surgery, coronary bypass, antibiotic prophylaxis (TC) 478 Trimethoprim, po: biotic effect (A) 154; with sulfamethox- Selegiline, compared with bromocriptine, Parkinson's disease Sympatholytic agents, adverse reactions, review (DSP) 969; azole, Pneumocystis carinii pneumonia (DIAS) 941 (FF) 38; compared with methixene, Parkinson's disease (FF) age (A) 532; alcohol withdrawal (DIAS) 31; beta-adrenergic Tryptophan, cosinophilia-myalgia syndrome, epidemiology 39; compared with tocopherol, Parkinson's disease (FF) 38; receptor response, racial groups (A) 824; pharmacokinetics (PEP) 1259 review (FF) 36 (DSP) 964; pharmacology (DSP) 962 Tuberculin, purified protein derivative, elderly (G) 650 Sepsis, ES monoclonal antibody, review (FF) 784; human mono: Sympathomimetic agents, age (A) 532; asthma, review (PA) Tuberculosis, ciprofloxacin (RPR) 919; elderly, review (G) 650 clonal antibody, review (FF) 778 997, beta-adrenergic receptor response, racial groups (A) 824 Tyrosine, cocaine abuse (A) 820 Sertraline, adverse reactions (FF) 957; compared with Systemic lupus erythematosus, drug-induced, review (L) 212 amitriptyline (FF) 954; interactions, review (FF) 958; pharma- cokinetics (FF) 953; pharmacology (FF) 952; review (FF) 952 Shaonn grMearwr,el lR aDlopwh (F.N,C )D is7t0i2n guished Pharmacy Educator, Mari- T U Short Reports, Acute Hemolysis and Renal Failure Following Discontinuous Use of Rifampin, 743; Altered Absorption of Digoxin, Sustained-Release Quinidine, and Warfarin with Su- Ulcers, decubitus, home care (A) 847 cralfate Administration, 745; Brachial Plexus Palsy with the thycardia, supraventricular, adenosine (DIAS) 749 University of California, San Francisco, clinical pharmacy pro- Use of Haloperidol and a Geriatric Chair, 1072; Chemical Tale, compared with bleomycin, malignant pleural effusion gram (SC) 308 Peritonitis Associated with Intraperitoneal Vancomycin, 602; (DIAS) 1188; compared with tetracycline, malignant pleural Urinary disorders, retention, ipratropium bromide (SR) 939, Conversion of Intravenous Ranitidine to Oral Therapy, 251; effusion (DIAS) 1188; malignant pleural effusion (DIAS) 1187 metoclopramide (SR) 469 Delirium in an Elderly Woman Possibly Associated with Ad- te, alteration, meperidine (L) 1137 Urokinase, neonatal thrombosis (PED) 853 ministration of Misoprostol, 133; Digoxin Assay Anomalies Teicoplanin, intravenous compared with intramuscular, skin, Urticaria, idiopathic, cimetidine (DIAS) 609 Due to Digoxin-Specific Fab Immunotherapy, 739; Effect of soft-tissue infection (RPR) 914 USPHS-CDC News (NC), Acute Allergic Reactions Associated I-Scrub on Signs and Symptoms of Chronic Blepharitis, 359; Teratogenicity, ofloxacin (SR) 1181; phenytoin (PED) 987 with Reprocessed Hemodialyzers—US, 1989-90, 572; AIDS Eradication of Methicillin-Resistant Staphylococcus aureus Testosterone, topical, microphallus (DIAS) 1341 in Europe, 114; AIDS in Women, 114; Cholera in the Western Vaginitis with Mupirocin, 1331; Flutamide-Induced Methe- Tetanus toxoid, anaphylaxis (L) 870 Hemisphere: Update and Recommendations for Treatment, moglobinemia, 600; Idioventricular Rhythm: Hypervagotonia Tetracycline, compared with talc, malignant pleural effusion 1294; Discontinuation of Parenteral Quinine from CDC, 906; Associated with Placebo, 471; In Vivo Inactivation of To- (DIAS) 1188; postantibiotic effect (A) 154 Measles Vaccination Levels Among Preschool-Aged Chil- 1438 © DICP,The Annals of Pharmacotherapy * 199] December, Volume 25 Index dren, 338; Mefloquine Dosing Regimen Changed, 450; Mor- Allen, Nancy M. (author) Clinical and Pharmacokinetic Profiles Bogaert, Marc G. (coauthor) see Vander Stichele, Robert H., tality Attributable to HIV Infection/AIDS, 338; Poisonings of Digoxin Immune Fab in Four Patients with Renal Impair- 1002 Associated with Illicit use of Gamma Hydroxy Butyrate, 114; ment (CR) 1315 Bollini, Paola (coauthor) see Muscettola, Giovanni, 296 Preventing Transmission of HIV and Hepatitis B Virus, 1157; Al-Nasser, Abdulaziz N. (author) Prescribing Patterns in Prima- Bond, William S. (author) Pharm.D.: All or Some? (L) 679 Publicly Funded HIV Counseling and Testing—US, 1990, ry Healthcare in Saudi Arabia (IR) 90 Bootman, J. Lyle (coeditor) see McGhan, William F., 80, 289, 1430; Streptomycin and Para-Aminosalicylic Acid, 1430; Alonso, Kenneth (coauthor) see Stajich, Gregory V., 14 414, 546 Treatment of Severe Plasmodium falciparum Infection with Alsar, Maria Jestis (coauthor) see Alvarez, Javier Soto, 558, Bosso, John A. (author) Academic Pharmacy Practice and Re Quinidine Gluconate, 906; Tuberculosis and HIV Infection: 1397 search (E) 1129; (author) Toxicity of Colistin in Cystic Fibro Anergy Testing and Patient Management, 1038 Altimiras, Juan (coauthor) see Duque, Alberto, 1009 sis Patients (RPR) 1168 USPHS News (NC), Pharmacy Consultation Program Available, Alvarez, Javier Soto (author) Aminoglycosides: Determination Brady, Silvia 1. (author) Calcitonin in Migraine (DIAS) 1185; 905 of New Therapeutic Ranges (L) 558; (author) Interferon Alfa- (author) Topical Aspirin for Postherpetic Neuralgia (DIAS) 2a-Induced Impotence (L) 1397 1077 Amarshi, Naseem (coauthor) see Peery, Patrick A., 1137 Braem, Marc D. (coauthor) see Vander Stichele, Robert H., V-Z AAomkait,o ,F reMda rYy. G(.c oa(uatuhtohorr)) sbeeo okG ryremvoinewp,r e6,8 3 Ruby E., 186 Bra1m0b0i2l la, Donald J. (coauthor) see Hemminki, Elina, 418 Appelt, Glenn D. (author) book review, 216 Brandon, Donald (coauthor) see Hull, Robert Lee, 135 Araujo, Oscar E. (author) Vitamin D Therapy in Psoriasis (A) Bressler, Linda R. (author) Misperceptions and Inadequate Pain Vancomycin, peritonitis (SR) 602; postantibiotic effect (A) 154; 835 Management in Cancer Patients (A) 1225 protein binding, Staphylococcus aureus (RPR) 713; rash (CR) Arbus, Gerald S, (coauthor) see Strong, Dawn K., 1175 Brett, Judy L. (coauthor) see Foran, Robert M., 546 1326; removal, hemofiltration (CR) 127 Ariano, Robert E. (author) Antimicrobial Prophylaxis in Coro- Briceland, Laurie L. (author) Cost Considerations of Conver Vaginitis, methicillin-resistant Staphylococcus aureus, mupiro- nary Bypass Surgery: A Critica! Appraisal (TC) 478 sion from Aminoglycoside-Containing Combination Regi- cin (SR) 1331 Arnau, Josep Maria (coauthor) see Balague, Montserrat, 871 mens to Ceftriaxone (L) 319; (author) Pentamidine-Associat- Vapreotide, analgesia (L) 1136 Artoux, Michelle J. (author) Alprostadil in Impotence (DIAS) ed Nephrotoxicity and Hyperkalemia in Patients with AIDS Varicella-zoster, diphenhydramine toxicity (CR) 130 363 (RPR) 1171 Vasodilating drugs, congestive heart failure, review (A) 1351 Aumaitre, Olivier (author) Preliminary Clinical Evidence for Briggs, Gerald G. (author) book review, 1017 Vecuronium, pharmacodynamics (A) 58; pharmacokinetics (A) Analgesic Effect of Vapreotide (L) 1136; (coauthor) see Bright, Thomas P. (author) Suspected Central Nervous System 59 Souweine, B., 1137 Toxicity from Inadvertent Nonsteroidal Antiinflammatory Verapamil, clearance, kidney failure (A) 1216; compared with Autret, Elisabeth (coauthor) see Jonville, Annie-Pierre, 1113 Drug Overdose (CR) 1066 adenosine, supraventricular tachycardia (DIAS) 749; migraine Avisar, Rahamim (author) Effect of I-Scrub on Signs and Bromley, Howard R. (coauthor) see Uber, Walter E., 357 prophylaxis (DIAS) 1076; premenstrual syndrome (DIAS) Symptoms of Chronic Blepharitis (SR) 359 Brown, Candace S. (author) Treatment of Attention Deficit Hy 361 Baciewicz, Anne M. (author) Conversion of Intravenous Raniti- peractivity Disorder: A Critical Review (DSP) 1207 Vidarabine, interaction, pegademase bovine, review (FF) 1094 dine to Oral Therapy (SR) 251 Brown, KimDebra (coauthor) see Araujo, Oscar E., 835 Vigabatrin, pharmacokinetics (A) 979; review (A) 984 Badir, Amin (coauthor) see Malnick, Stephen D.H., 869 Brown, Rex O. (coauthor) see Broyles, Joyce E., 119 VIP News (NC), Abate, Marie A., 450; Baker, Danial E., 450; Bahal, Neeta (author) The Role of Corticosteroids in Infants and Broyles, Joyce E. (author) Pharmacist Interventions Improve Beck, Diane E., 572; Benet, Leslie Z., 572; Campbell, R. Children with Bacterial Meningitis (PED) 542 Fluid Balance in Fluid-Restricted Patients Requiring Parenter- Keith, 1038; Carmichael, Jannet M., 1431; Clayton, Anne G., Bailie, George R. (coauthor) see Briceland, Laurie L., 1171: al Nutrition (RPR) 119 572; Covington, Timothy R., 1431; Edwards, David J., 1038; (coauthor) see Lomaestro, Ben M., 1249; (coauthor) see Brundage, Dianne M. (coauthor) see Uber, Walter E., 357 Emswiller, Carl F, Jr., 1431; Finley, Rebecea S., 1431; Smith, Thomas A. II, 602 ®rundage, Richard C. (coauthor) see Uber, Walter E., 357 Graves, Nina M., 1038; Hart, Linda L., 450; Kaul, Alan F., Baker, Danial E. (coauthor) see Garrison, Mark W., 617 Brushwood, David B. (author) The Duty to Counsel: Reviewing 1431; Kelly, William N., 1431; Knapp, David A., 906; Lake, Balagué, Montserrat (author) Pseudomonas aeruginosa Resis- a Decade of Litigation (SC) 195 Kathleen D., 450; Lamp, Kenneth, 1038; Lopez, Larry M., tance to Ceftazidime (L) 871 Brusko, Cynthia S. (author) Ketoconazole Hepatotoxicity in a 1038; McGhan, William F., 450, 906; Nahata, Milap C., 572; Ballow, Charles H. (coauthor) see Leo, Raphael J., 351 Patient Treated for Environmental Illness and Systemic Can- Ponte, Charles D., 572; Rybak, Michael J., 1038; Schentag, Balmer, Carol McManus (author) Clinical Use of Biologic Re didiasis (CR) 1321 Jerome J., 1038; Shangraw, Ralph F., 702; Smith, Gary H., sponse Modifiers in Cancer Treatment: An Overview. Part IL. Bryson, Scott M. (author) Therapeutic Monitoring and Pharma 450; Smith, William E., 906; Thompson, Dennis F., 450 Colony-Stimulating Factors and Interleukin-2 (DSP) 490 cokinetic Evaluation of Procainamide in Neonates (PED) 68; Vitamin D, psoriasis (DIAS) 753, review (A) 835; toxicity (A) Baltz, Julie K. (coauthor) see Minor, James R., 41 (coauthor) see Strong, Dawn K., 1175 837 Baptista, Richard J. (coauthor) see Driscoll, David F., 276 Buck, Marcia L. (author) Phenothiazine-Associated Apnea in Vitamin E, anticonvulsant (DIAS) 362 Barbarash, Rick A. (author) Correction: Mechanical Ventila- Two Siblings (CR) 244; (author) Prostaglandin E, Treatment Vitamin K,, anaphylaxis (L) 871 tion (L) 1017 of Congenital Heart Disease: Use Prior to Neonatal Transport Volmax, release rate (L) 438 Barber, Peter G. (coauthor) see Etzel, Joseph V., 1341 (PED) 408 Wagner, John G., career retrospective (SC) 1265 Barbier, Pascaline (coauthor) see Jonville, Annie-Pierre, 1113 Warfarin, interaction, ciprofloxacin (L) 1397, nafcillin (CR) Barlow, Jared C. (coauthor) see Watson, William A., 463 598; internaticsal normalized ratio, interlaboratory effects Barreuther, Alan D. (coauthor) see Raisch, Dennis W., 716 C-D (TC) 1190; therapy institution, deep vein thrombosis (L) Batty, Kevin T. (author) Evaluation of Generic-Brand Name 1397; with digoxin/quinidine, interaction, sucralfate (SR) 745 Knowledge (L) 1138 Withdrawal, see Drug withdrawal Baumann, Terry J. (author) Meperidine Serum Concentrations Women, AIDS, incidence (NC) 114 and Analgesic Response in Postsurgical Patients (RPR) 724 Campbell, G. Douglas, Jr. (coauthor) see Olsen, Keith M., 784 Xamoterol, congestive heart failure, review (A) 1352 Bavoux, Frangoise (coauthor) see Jonville, Annie-Pierre, 1113 Canals, Antonio Mirada (author) Methyldopa-Induced Granu- Zidovudine, clearance, kidney failure (A) 1217; utilization Bawazir, Saleh A. (author) Comparative Study of Saudi-Mar- lomatous Hepatitis (L) 1269 (PEP) 1374 keted Products and US Drug Labeling (IR) 863 Cantu, Thomas G, (author) Caffeine in Electroconvulsive Ther Zimbabwe, drug information center, establishment (IR) 1379; Beardsley, Robert S. (coauthor) see Hohmann, Ann A., 85 apy (DIAS) 1079 pharmacy education, practice (IR) 302 Beckley, DennisJ . (coauthor) see Edelstein, Howard E., 1007 Cardoni, Alex A, (author) Pharm.D.: All or Some? (L) 679 Zine, interaction, quinolones (DIR) 1253 Bégaud, Bernard (coauthor) see Haramburu, Francoise, 214, Carter, Charles A, (author) book review, 1275 875 Cassano, Karen B, (coauthor) see Edelstein, Howard E., 914 Beijnen, Jos H. (author) Visual Compatibility of Ondansetron Catala, Jesus (coauthor) see Sanchis, Amparo, | 137 and Dexamethasone (L) 869 Cerda-Trias, M® Teresa (coauthor) see Lleonart-Bellfill, Ra- Belitsky, Philip (coauthor) see Dugandzic, Rose M., 316 mon, 870 AUTHOR INDEX Bell, Charles N., Jr. (coauthor) see Rae, Charlesworth E., 932 Cetnarowski-Cropp, Anne B. (author) Quinapril: A New Sec Bell, Jeffrey M. (coauthor) see Peterson, Andrew M., 1334 ond-Generation ACE Inhibitor (FF) 499 Ben-Amitai, Dan (author) Neonatal Fever and Cyanotic Spells Chaffee, Bruce W. (coauthor) see Kirking, Duane M., 80, 682 from Maternal Chlorpromazine (L) 1009 Chan, C.Y. Jennifer (author) Diphenhydramine Toxicity in A-B Benet, Leslie Z. (author) Ideals and Innovation: Drugs, Gener- Three Children with Varicella-Zoster Infection (CR) 130 ics, the FDA, and the Pharmacist (RC) 427 Chan, Cheng L. (coauthor) see Chow, Moses S.S., 613 Ben-Noun, Liubov (author) Unresponsiveness to Nifedipine Chan, Gary L. (author) Effect of Plasmapheresis on Cy Treatment (L) 99 closporine Pharmacokinetics (L) 211 Abel, Steven R. (author) Evaluation of an Imipenem/Cilastatin Benson, Jill M. (author) The Impact of Changing Ventilator Pa- Chareyre, Stéphane (coauthor) see Schott, Anne Marie, 600 Target Drug Program (RPR) 348 rameters on Availability of Nebulized Drugs in an In Vitro Chirurgi, Valerie A. (coauthor) see Edelstein, Howard E., Abou-Auda, Hisham §, (coauthor) see Bawazir, Saleh A., 863 Neonatal Lung System (PED) 272 914, 1007 Ackerman, Bruce H. (author) Accumulation of 3-Hydroxy- Berardi, Rosemary R. (coauthor) see Kirking, Duane M., 80, Chow, Moses S.S, (author) The Controversy of Heparin Thera quinidine Following Chronic Quinidine Therapy (L) 867; (au 682 py as an Adjunct to Thombolysis in Acute Myocardial Infare thor) book review, 1401; (author) Monitoring Chronic Outpa- Berg, Mary J. (coauthor) see Van Dyke, Don C., 987 tion (TC) 613 tient Infections: Providing Comprehensive Home Healthcare Berman, Alex (author) book review, 683 Choy, Melissa (author) Cimetidine in Idiopathic Urticaria Pharmacy Services (A) 840 Bero, Christopher J. (author) Possible Association of Pul (DIAS) 609 Adair, Colin G, (author) book review, 878 monary Fibrosis with Mexiletine (SR) 1329 Chrischilles, Elizabeth A. (coauthor) see Semla, Todd P., 410 Adelman, Martin H. (coauthor) sce Schentag, Jerome J., 1050 Bertrand, Philippe (coauthor) see Jonville, Annie-Pierre, 1113 Christensen, Sharon (coauthor) see Stein, Gary E., 582 Ahmad, Saeed (author) Enalapril-Induced Acute Psychosis (L) Biarez, Odile (author) Comparison and Evaiuation of Nine Bib- Cister6-Bahima, Anna (coauthor) see Lleonart-Bellfill, Ra- 558; (author) Famotidine and Cardiac Arrhythmia (L) 315; liographic Databases Concerning Adverse Drug Reactions mon, 870 (author) Fluoxetine and Glaucoma (L) 436 (RPR) 1062 Cocchetto, David M. (coauthor) see Rue, Peter J., 438 Ajileye, Isaac (coauthor) see Hitchen, Karen, 1398 Bistrian, Bruce R. (coauthor) see Driscoll, David F., 276 Colbert, James, Jr. (author) We Use Drugs Too—More Pedi Albrecht, Lisa M. (author) Vancomycin Protein Binding in Pa- Bivins, Brack A. (coauthor) see Baumann, Terry J., 724 atric Information in Review Articles (L) 559 tients with Infections Caused by Staphylococcus aureus Bjornson, Darrel C. (author) The Relationship Between Outpa Collin, Kathleen (coauthor) see Levine, Marc, 743 (RPR) 713 tient Drug Costs and Disease Progression in the Human Im- Colucci, Robert D. (coauthor) see Ujhelyi, Michael R., 1047 Alerany, Carmen (coauthor) see Zara, Corinne, 662 munodeficiency Virus-Infected Population (PEC) 414 Conner, Dale P. (author) book review, 217 Alexander, Bruce (coauthor) see Perry, Paul J., 1270 Black, David R. (author) Purdue Stepped Approach Model: Ap- Conrad, Stephen D. (coauthor) see Peterson, Andrew M., Alexander, Michael R. (author) Comment: Pharm.D.: All or plication to Pharmacy Practice (A) 164 1334 Some? (L) 1400 Blackburn, George L. (coauthor) see Driscoll, David F., 276 Cool-Foley, Alicia A, (author) Eradication of Methicillin-Resis Al-Hassan, Mohammed I. (coauthor) see Bawazir, Saleh A., Blume, Robert P. (coauthor) see Keys, Patricia A., 1101 tant Staphylococcus aureus Vaginitis with Mupirocin (SR) 863 Blumer, Jeffrey L. (coauthor) see Buck, Marcia L., 244; 1331 Al-Khamis, Khalil I. (coauthor) see Bawazir, Saleh A., 863 (coauthor) see Reed, Michael D., 344 Corelli, Robin L. (author) Medication Usage Patterns in Pa DICP, The Annals of Pharmacotherapy s 1/99] December, Volume25 ® 1439 tients with Human Immunodeficiency Virus Infection: A Eselin, Julie (author) Talc in the Treatment of Malignant Pleural Godley, Paul J. (author) Evaluation of Three Theophylline Dos- Comparison of Patient Reported Medication Usage with Med- Effusion (DIAS) 1187 ing Methods in Pediatric Patients (PED) 179; (coauthor) see ical Chart Review (PEP) 1374 Espinach, Joan (coauthor) see Nafria, Esteve Colomé, 870 Wasan, Suman M., 942 Cornish, Laura A, (coauthor) see Kirking, Duane M., 80, 682 Etienne, Jean (coauthor) see Biarez, Odile, 1062 Godley, Susan E. (coauthor) see Godley, Paul J., 179 Coulston, Daniel R. (author) Hepatitis B Vaccine (O) 671 Etzel, Joseph V. (author) Topical Uses of Testosterone (DIAS) Goldspiel, Barry R. (author) Goserelin Acetate Implant: A De- Craft, Alan W. (coauthor) see Kohli-Kumar, Mudra, 469 1341 pot | ig Hor ig Hormone Analog for Ad- Crismon, M. Lynn (coauthor) see Volf, Nora, 948 Ewing, James R. (coauthor) see Fagan, Susan C., 1299 vanced Prostate Cancer (FF) 796; (coauthor) see Kohler, Cummings, Doyle M. (coauthor) see Ujhelyi, Michael R., 1047 Fagan, Susan C. (author) Assessing the Effects of Antihyper- David R., 367 Curet, Luis B. (coauthor) see Gauger, Laura J., 456 tensive Medication on Cerebral Blood Flow: Di in Goldstein, Harvey R. (coauthor) see Van Slooten, Andrea D., Curry, Monica L. (author) I ion of Phenothi and Re- Internal Carotid Artery Occlusion (RPR) 1299; (author) Ni- 578 lated Drugs and Caffeinated Beverages (L) 437 modipine and Bradycardia in Acute Stroke—Drug or Dis- Gonzalez, Edgar R. (author) The Dose of Epinephrine During Curry, Stephen H. (coauthor) see Curry, Monica L., 437 ease? (CR) 247 Cardiopulmonary Resuscitation in Humans: What Should It Cutler, Neal R. (author) Idioventricular Rhythm: Hypervagoto- Faulkner, Thomas P. (coauthor) see Gundlach, Catherine A., Be? (TC) 773 nia Associated with Placebo (SR) 471 1231 Gooch, W. Manford, III (coauthor) see Reed, Michael D., 344 Czachor, John S. (coauthor) see Dallal, Mohammed M., 594 Fazio, Anthony (coauthor) see Rae, Charlesworth E., 27 Goodless, Dean R. (author) Ketoconazole in the Treatment of Dallal, Mohammed M. (author) Aztreonam-Induced Myelosup- Feld, Steven (coauthor) see Shapira, Oz M., 354 Pityriasis Versicolor: International Review of Clinical Trials pression During Treatment of Pseudomonas aeruginosa Pneu- Felts, Nancy (coauthor) see Peery, Patrick A., 1137 (A) 395 monia (CR) 594 Fialip, Joseph (coauthor) see Aumaitre, Olivier, 1136; (coau- Goodman, Robert P. (coauthor) see McKenney, James M., 234 D’ Amico, Frank (coauthor) see Shaughnessy, Allen F., 17 thor) see Souweine, B., 1137 Goswami, Amar (coauthor) see Olson, Lisa A., 100 Danziger, Larry H. (coauthor) see Shwed, Jill A., 10 Fiedler, Jill B. (coauthor) see Grasela, Thaddeus H. Jr., 857 Goyan, Jere E. (coauthor) see Day, Robert L., 308, 1142 Dasta, Joseph F. (author) book review, 105; (author) Pharma- Fields, Suzanne M. (author) Idarubicin: A Second-Generation Gozzo, Isabelle (coauthor) see Schott, Anne Marie, 600 cist Involvement in Society of Critical Care Medicine (L) Anthracycline (FF) 505 Gradon, Jeremy D. (author)N leptic Mali Synd: 1398; (editor) Critical Care Therapeutics, 169, 276, 1231 Figg, William D. (author) Aseptic Meningitis Associated with Possibly Caused by Molindone Hydrochloride (SR) ‘1071 Davies, John M. (coauthor) see Gilleece, Maria H., 867 Muromonab-CD3 (L) 1395; (author) Peripheral Neuropathy in Graham, Lynn (author) book review, 1275 Davis, Robin L. (coauthor) see Raymond, Glynn G., 123 HIV Patient After Isoniazid (L) 100; (coauthor) see O’Quinn, Grant, Alexander C. (coauthor) see Thomson, Alison H., 127 Day, Robert L. (author) Authors’ Reply: Origins of Clinical Stephen V., 1272; (coauthor) see Williams, Dennis M., 1140 Grasela, Thaddeus H., Jr. (author) Clinical and Economic Im- Pharmacy (L) 1142; (author) The Origins of the Clinical Phar- Figueras, Albert (coauthor) see Balague, Montserrat, 871 pact of Oral Ciprofloxacin as Follow-Up to Parenteral Antibi- macy Program at the University of California, San Francisco Findlay, John W.A. (coauthor) see Allen, Nancy M., 1315 otics (PEP) 857 (SC) 308 Finley, Rebecca S. (coauthor) see Hood, Michele A., 518 Grassmick, Bradford K. (coauthor) see Tutag-Lehr, Victoria, Dean, Richard R. (coauthor) see Malesker, Mark A., 231 Fitzgerald, Jill Mancini (author) Authors’ Reply: Mesalamine 25 Decker, David A. (coauthor) see Umstead, Greg S., 249 in Ulcerative Colitis (L) 1015; (author) Mesalamine in Ulcera- Grasso, Robert A. (author) Relationship Between Tranyl- DeJong, Douglas J. (coauthor) see Sayler, Debra J., 436 tive Colitis (FF) 140 cypromine Sulfate Dose and Mi ine Oxidase Inhibiti Delgadillo, Joaquim (coauthor) see Nafria, Esteve Colomé, Flowers, Franklin P. (coauthor) see Araujo, Oscar E., 835; (L) 99 870 (coauthor) see Goodless, Dean R., 395 Gratz, Irwin (coauthor) see Larijani, Ghassem E., 54 Delgado, Fernando (coauthor) see Martinez-Abad, Manuel, Flowers, Melinda K. (coauthor) see Taylor, David M., 212 Grau, Enric (coauthor) see Pastor, Emilio, 1136 871 Floyd, Ronald A. (author) Comment: Aminoglycoside Dosing Graves, Nina M. (author) Antiepileptic Medications in Devel- Delmas, Pierre D. (coauthor) see Schott, Anne Marie, 600 (L) 1141 opment (A) 978 Del Valle, Oscar (coauthor) see Balague, Montserrat, 871 Fogarty, Patricia M. (coauthor) see Hennessy, Sean, 678 Green, Jeffrey A. (author) The Healthcare Professional of the Destache, Christopher J. (coauthor) see Malesker, Mark A., Fonollosa, Vinceng (coauthor) see Nafria, Esteve Colomé, 870 Future: Function Based upon Competence (O) 205 231 Foran, Robert M. (author) Evaluating the Cost Impact of Intra- Green, Paul J. (coauthor) see Ujhelyi, Michael R., 1047 Deutsch, David (coauthor) see Avisar, Rahamim, 359 venous Antibiotic Dosing Frequencies (PEC) 546 Greenblatt, Ruth M. (coauthor) see Corelli, Robin L., 1374 Dielman, Debra G. (coauthor) see McCullough, Jill M., 1326 Franson, Kari L. (author) Cyclosporine in Graves’ Ophthal- Gribnau, Frank W. (coauthor) see Pouwels, Marie-Jose M., Dolgin, Jili G. (author) Pharmacokinetic Simulation of the Ef- mopathy (DIAS) 750 1043 fect of Multiple-Dose Activated Charcoal in Phenytoin Poi- Friedman, Shmuel (coauthor) see Peled, Yoav, 1181 Griffin, James H. (author) Lisinopril-Induced Lithium Toxicity soning—Report of Two Pediatric Cases (PED) 646 Froese, Emerson H. (coauthor) see Jameson, John P., 302 (L) 101; (coauthor) see Hahn, Susan M., 1273 Dordain, Gerard (coauthor) see Aumaitre, Olivier, 1136 Fryer, Nancy L. (coauthor) see Umstead, Greg S., 249 Grymonpre, Ruby E. (author) Prescribing Patterns for Older Doreau, Christian G. (coauthor) see Biarez, Odile, 1062 Fujita, Takuo (coauthor) see Shiozawa, Shunichi, 101 Heavy Drug Users Living in the Community (G) 186 Dorevitch, Abraham (author) Mania Associated with Clon- Fuller, Dennis K. (coauthor) see Levinson, Miriam L., 657 Guba, Elizabeth A. (coauthor) see Abel, Steven R., 348 azepam (SR) 938 Fuller, Matthew A. (author) Selegiline: Initial or Adjunctive Gubara, Othman A. (coauthor) see Bawazir, Saleh A., 863 Draugalis, JoLaine R. (coauthor) see Jones-Grizzle, Amy J., Therapy of Parkinson’s Disease (FF) 36 Gugliel B. Joseph hor) see Corelli, Robin L., 1374 289 Guharoy, Sudip Roy (author) Drug Company Influence (L) Drees, Christine A. (author) Aseptic Meningitis and 1138; (author) Pharm D: All or Sone? (L) 679; (author) Muromonab-CD3 Therapy (DIAS) 138 G-H Streptokinase Versus Recombinant Tissue-Type Plasminogen Driscoll, David F. (author) Parenteral Nutrient Admixtures as Activator (L) 1271 Drug Vehicles: Theory and Practice in the Critical Care Set- Gumbhir, Ashok K. (coauthor) see Kucukarslan, Suzan N., ting (CC) 276 213 Driver, Paul S. (author) Depression Treatment in Parkinson's Gal, Peter (author) Indomethacin Therapy for Intraventricular Gums, John G., (coauthor) see Rey, Aixa M., 745 Disease (DIAS) 137 Hemorrhage in Neonates: Another Use for that “Old” Drug Gundlach, Catherine A. (author) Charge and Reimbursement Duchene-Marullaz, Pierre (coauthor) see Aumaitre, Olivier, (E) 1385; (author) Neonatal Thrombosis: Treatment with Hep- Analysis for Intensive Care Unit Patients in a Large Tertiary 1136 arin and Thrombolytics (PED) 853; (coauthor) see Benson, Teaching Hospital (CC) 1231 Dugandzic, Rose M. (author) Effect of Coadministration of Acy- Jill M., 272 Guthrie, Sally K. (author) book review, 878; (author) Sertra- clovir and Cyclosporine on Kidney Function and Cyclosporine Galinsky, Raymond E. (author) Pharmacists and the Mandate line: A New Specific Serotonin Reuptake Blocker (FF) 952 Concentrations in Renal Transplant Patients (L) 316 of Pharmaceutical Care (O) 431 Hadsall, Ronald S. (coauthor) see Black, David R., 164 Dugoni-Kramer, Bonnie M. (author) Ciprofloxacin—Warfarin Gandhi, Dipeshkumar K. (coauthor) see Cutler, Neal R., 471 Hahn, Nancy W. (coauthor) see Whelan, Anne Marie, 638 Interaction (L) 1397 Gannon, Joan M. (coauthor) see Hilleman, Daniel E., 1096 Hahn, Susan M. (author) Comment: Fluoxetine Adverse Effects Dukes, George E. (coauthor) see Graham, Lynn, 1275 Gannon, Patrick M. (coauthor) see Sesin, G. Paul, 872 and Drug Interactions (L) 1273; (coauthor) see Griffin, Dunham, Gary D. (coauthor) see Allen, Nancy M., 1315 Garcia-Cases, Carlos (coauthor) see Duque, Alberto, 1009 James H., 101 Dunn, Marvin I. (coauthor) see Howard, Patricia A., 929 Gardner, Stephanie F. (author) Medical Versus Pharmaceutical Haley, Christopher J. (coauthor) see Drees, Christine, 138 Dupuis, Robert E. (coauthor) see Roush, Maura Kraynak, Continuing Education: Are Both Appropriate for the Pharma- Hamilton, Robert A. (author) book review, 440 473 cist? (SR) 1336 Hansen, Charles J. (coauthor) see Benson, Jill M., 272 Duque, Alberto (author) Vertigo Caused by Intravenous Garrelts, James C. (author) Clofazimine: A Review of Its Use Hansen, Lea Ann (author) Altretamine (FF) 146 Imipenem/Cilastatin (L) 1009 in Leprosy and Mycobacterium avium Complex Infection (FF) Haramburu, Francoise (author) Authors’ Reply: Manual Ver- sus Computer-Based Literature Searches for Adverse Drug E-F Garrison, Mark W. (author) Therapeutic Advances in the Pre- Reactions (L) 875; (author) Manual or Computer-Based Liter- vention of Hepatitis B: Yeast-Derived Recombinant Hepatitis ature Searches: Is One Best for Pharmacovigilance? (L) 214 B Vaccines (A) 617 Harding, Godfrey K.M. (coauthor) see Zhanel, George G., Gauchez, Anne-Sophie M. (coauthor) see Jonville, Annie- 153 Pierre, i113 Harralson, Arthur F. (coauthor) see Kehoe, William A., 1368 Edelstein, Howard E. (author) Adverse Reactions to Phenothi- Gauger, Laura J. (author) Comparative Efficacy of Intravaginal Harris, Jennifer Meyer (author) Correction: Clonidine Patch azine Antiemetics in AIDS (L) 1007; (author) Intravenous or Prostaglandin E, in the Gel and Suppository Forms for Cervi- Toxicity (L) 682 Intramuscular Teicoplanin Once Daily for Skin and Soft-Tis- cal Ripening (RPR) 456 Harrison, Gunyon M. (coauthor) see Bosso, John A., 1168 sue Infections (RPR) 914 Geraci, Mark C. (coauthor) see Bressler, Linda R., 1225 Hart, Linda L. (author) Correction: Dipyridamole in Angioplas- Edmunds, Marilyn W. (author) book review, 1018 Ghanem, Jihad (coauthor) see Heyman, Samuel N., 1068 ty (L) 1274; (coauthor) see Brady, Silvia I., 1185; (coauthor) Edwards, David J. (coauthor) see Albrecht, Lisa M., 713; Gibson, Gene A. (coauthor) see Munar, Myrna Y., 1306 see Lee, Audrey F., 361; (coauthor) see Teruya, Jody L (coauthor) see Touchette, Mark A., 104 Gilbert, Robert P. (coauthor) see Hegman, Greg W., 2! 747; (coauthor) see Wiehl, Wendy, 362; (editor) DIAS Edwards, George A. (coauthor) see Godley, Paul J., 179 Gilleece, Maria H. (author) Mesna Therapy and Hypertension Rounds, 30, 137, 253, 361, 473, 606, 747, 941, 1076, 1185, Eisele, George (coauthor) see Smith, Thomas A. II, 602 (L) 867 1339 Eisenstat, David D. (coauthor) see Strong, Dawn K., 1175 Gilman, Jamie T. (author) Carbamazepine Dosing for Pediatric Hartshorn, Edward A. (editor) Drug Interactions and Reactions Elis, Avishay (author) Agranulocytosis Associated with Seizure Disorders: The Highs and Lows (PED) 1109 Update, 191, 657, 1249 Enalapril (CR) 461 Givner, Morris L. (coauthor) see Dugandzic, Rose M., 316 Hartzema, Abraham G. (editor) Pharmacoepidemiology, 85, Elliott, Clyde E. (coauthor) see Rae, Charlesworth E., 932 Glazier, Howard S. (author) Comment: Parenteral H-Receptor 296, 418, 857, 1113, 1259, 1374 Engen, Phillip L. (coauthor) see Howard, Patricia A., 929 Antagonist Intervention (L) 681 Harvey, John L. (author) Comparative Attitudes to Verbal and Erdman, Sharon M. (author) Trimethoprim/Sulf: | Glenarkis, Dean G. (author) Ketorolac Formulary Restriction Written Medication Information Among Hospital Outpatients Concentrations in Pneumocystis carinii Pneumonia (DIAS) and Usage Evaluation (L) 1399 (RPR) 925 941 Gloudeman, Mark W. (coauthor) see Edelstein, Howard E., Hatoum, Hind T. (author) Patient Outcome and the Future Erickson, Steven R. (author) Hyp and Bradycardia Pos- 1007 Practice of Pharmacy (O) 208 sibly Associated with Intraocular Injection of Acetylcholine Goad, Janet D. (coauthor) see Kucukarslan, Suzan N., 213 Hatton, Randy C. (author) Comment: Manual Versus Comput- (CR) 1178 Godin, Marie-Héléne (coauthor) see Haramburu, Francoise, er-Based Literature Searches for Adverse Drug Reactions (L) Eschalier, Alain (coauthor) see Aumaitre, Olivier, 1136 214, 875 875 1440 = DICP, The Annals of Pharmacotherapy ® 1991 December, Volume 25